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1.1 Ischemic preconditioning 
 
Many studies in vivo and in vitro have demonstrated that neurons exposed to brief 
periods of sublethal anoxia develop resistance to subsequently more prolonged and 
lethal anoxic insults (Kitagawa et al., 1991; Kitagawa et al., 1990; Gidday et al., 1994) 
(Fig.1). This phenomenon, known as anoxic preconditioning (APC), was first described 
in the myocardium (Murry et al., 1986; Meldrum et al., 1997) and only recently in the 
brain (Kirino et al., 1991; Kitagawa et al., 1991; Meller et al., 2005). Consequently, over 
the last three decades, many efforts have been addressed to identify the molecular 
mechanisms involved in this phenomenon in order to open up therapeutic avenues for 
the treatment of cerebral ischemia.  
 
 
      Dirnagl et al., TINS 26: 248, 2003 
 
Fig. 1 Ischemic tolerance is an evolutionary conserved cellular defense program in which exposure to 
a subtoxic insult (the preconditioning stimulus) results in resistance to a subsequent lethal stressor. 
 
 
 
Fig.1 
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1.1.1 Ischemic preconditioning stimuli 
 
Differences in the intensity, duration, and/or frequency of a particular stress 
stimulus determine whether that stimulus is too weak to elicit any response, or sufficient 
magnitude to serve as a preconditioning trigger, or too robust and therefore harmful 
(Dirnagl et al., 2003) (Fig.2). It is generally accepted that preconditioning requires small 
doses of an otherwise harmful stimulus to induce protection against subsequent injurious 
challenge (Dahl et al., 1964). Several distinct preconditioning stimuli can induce 
tolerance to ischemic brain injury; among them are non injurious ischemia, cortical 
spreading depression, brief episode of seizure, exposure to anaesthetic inhalants, and 
low doses of endotoxin, hyperthermia or heat shock (Garnier et al., 2003).  
 
 
Dirnagl et al., Lancet Neurol 2009; 8: 398–412 
 
Fig. 2 Signalling cascades of preconditioning. Various stimuli lead to protection via modules of sensors, 
transducers, and effectors. Adapted from Dirnagl et al, with permission from Elsevier.  
Fig.2 
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The existence of multiple, diverse preconditioning stimuli able to provide 
protection against an entirely different type of injury, constitutes the well-known 
phenomenon of ‘cross-tolerance’ (Schurr et al., 1986). Accordingly, one stressor can 
promote cross-tolerance to another, or the same stressors that elicit tolerance in the brain 
can elicit tolerance in other organs. Many exogenously delivered chemical 
preconditioning agents, such as inflammatory cytokines and metabolic inhibitors, can 
also induce ischemic tolerance, raising the possibility that in the future it will be possible 
to activate pharmacologically these distal pathways in the human brain.  
Moreover, because inducers and mechanisms of tolerance might have similar 
features, the induction of tolerance in one organ can, via neural or paracrine 
mechanisms, spread to other organs. This phenomenon, known as ‘remote 
preconditioning’ or ‘preconditioning at a distance’, has been recently described both in 
the brain and in the myocardium after hind limb ischemia or intrarenal occlusion of the 
aorta, respectively. Differences in the intensity, duration and/or frequency of a particular 
stimulus potentially able to induce protection determine whether that stimulus is too 
weak to elicit a response, of sufficient intensity to serve as a preconditioning trigger, or 
too robust to be harmful. 
In general, it is widely accepted that immediate acquisition of protein-synthesis-
independent tolerance is mediated by post-translational modification and that the 
effective duration is brief. Conversely, there is general agreement that delayed induction 
of ischemic tolerance requires new protein synthesis and is sustained for a time interval 
ranging from a few days to a few weeks. In the brain, the time course of ischemic 
tolerance apparently follows the delayed pattern, suggesting that synthesis of active 
proteins may be necessary for full development of ischemic tolerance (Endres et al., 
2003). Once induced, the ischemic tolerance is believed to last for a few days and to 
diminished gradually a few weeks after acquisition (Ding et al., 2005). 
 
a) Sensors and transducers 
 
To induce tolerance, the preconditioning stimulus must be recognized by 
molecular sensors as a sign of something potentially much more severe to come. So far, 
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numerous types of sensor have been identified, including neurotransmitter, 
neuromodulator, cytokine and toll-like receptors (Kariko et al., 2004), as well as ion 
channels and redox-sensitive enzymes (see the figure below). In turn, these sensors 
activate transduction pathways that initiate the adaptive response.  
Although dependent in part on the nature of the preconditioning stimulus, 
members of these transduction pathways for which there is strong general support 
include mitogen-activated protein kinases (MAPKs) and their phosphorylated Ras, Raf, 
MEK and ERK subfamilies (Gonzalez-Zulueta et al., 2000; Jones et al., 2004), 
mitochondrial ATP-sensitive K+ (KATP) channels (Heurteaux et al., 1995; Yoshida et 
al., 2004), Akt (also known as protein kinase B) (Yano et al., 2001; Wick et al., 2002) 
and the protein kinase C-ε isoform (Raval et al., 2003).  
The possibility that the nitric oxide-based adaptive response to hypoxia in 
Drosophila is evolutionarily conserved, suggests that this multifunctional modulator 
might be a logical choice as an autocrine and paracrine mediator of preconditioning 
stress. Indeed, pharmacological and genetic evidence supporting the involvement of 
nitric oxide (derived from the endothelial (Gidday et al., 1999), neuronal (Atochin et al., 
2003) and inducible isoforms of nitric oxide synthase (NOS) in the transduction process 
is continuing to mount.  
Given the redox sensitivity of many kinases and transcription factors, reactive 
oxygen species might also serve as transducers.  
Adenosine, another prototypical paracrine mediator and ‘retaliatory metabolite’, 
the production of which is linked to ATP degradation, seems integral to tolerance 
induction in some models (Yoshida et al., 2004; Nakamura et al., 2004).  
Finally, caspases might be essential induction catalysts, given that cyclic AMP 
responsive element-binding protein (CREB), the p50 and p65 subunits of nuclear factor-
κB (NF-κB), and protein kinase C and other kinases are caspase substrates (McLaughlin 
et al., 2003). Notably, some of the aforementioned molecular transducers and signalling 
intermediates also serve as post-ischemic effectors of the ischemia-tolerant phenotype 
(Dirnagl et al., 2003).  
Preconditioning-activated signalling pathways converge to induce post-
translational modifications of existing proteins and/or to activate transcription factors 
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that drive the genomic response. Several transcription factors are known to be sensitive 
to regulation by hypoxia/ischemia and probably participate in this response, including 
activating protein 1 (AP1), CREB, NF-κB (Ravati et al., 2001; Blondeau et al., 2001), 
early growth response 1 and the redox-regulated transcriptional activator SP1 (Fig. 11).  
However, the hypoxia-inducible factor (HIF) isoforms have garnered the most 
experimental support so far with respect to mediating the transactivation of adaptive, 
pro-survival genes, particularly those involved in glucose metabolism and angiogenesis 
(Liu et al., 2005). Transcriptional regulation of the genome by HIF is similar in 
Drosophila, C. elegans and mammals. In mammals, the HIF1α isoform is hydroxylated 
during normoxia by an oxygen- and iron-dependent prolyl hydroxylase, allowing 
interaction between HIF1α and an ubiquitin ligase that targets HIF1α for degradation by 
the proteasome pathway. However, hypoxia renders the hydroxylase enzyme non 
functional, and HIF1α, no longer able to associate with the ligase in its non hydroxylated 
form, then enters the nucleus, dimerizes with HIF1β, and promotes the transcription of 
genes that enhance hypoxic resistance. Prolyl hydroxylase inhibitors, such as 
deferroxamine, cobalt chloride and other ‘HIF-mimetics’ are therefore attracting 
attention as potential preconditioning therapeutics.  
The HIF2α isoform is regulated in a similar way. It exists primarily in endothelial 
cells and, although it seems to be important in embryonic vasculogenesis, it does not 
seem to be induced in response to hypoxia in the neonate brain (Bernaudin et al., 2002) 
as it is in the adult brain (Wiesener et al., 2003). Details regarding transcriptional 
regulation by HIF2α are still unclear; although it may co-transactivate some genes with 
HIF1α, through the influence of kinases and other regulators, HIF2α might be more 
active on the promoters of endothelial cell-specific survival genes (Ralph et al., 2004) 
associated with angiogenesis, vascular remodelling, and endothelial cell homeostasis. 
 
b) Effectors and genomic reprogramming 
 
The induction of ischemic tolerance is accompanied by substantial change in gene 
expression, suggesting that preconditioning stimulates a fundamental genomic 
reprogramming of cells that confers cytoprotection and survival (Stenzel-Poore et al., 
2007). The genomic response after ischemic preconditioning is a signature of the 
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complex interplay of multiple signalling pathways, highly specialized in different cell 
types of the brain seem to refine the cellular and systemic response to combat the 
noxious stimulus. Hundreds of genes are either upregulated or downregulated in 
response to ischemic preconditioning stimuli (Bernaudin et al., 2002; Tang et al., 2006). 
Changes in gene expression differ between harmful ischemia and ischemic 
preconditioning (Stenzel-Poore et al., 2003). Tolerance induced by ischemic 
preconditioning changes the expression of genes involved in the suppression of 
metabolic pathways, immune responses, ion-channel activity and it is regulated by 
transcription factors but also depends on epigenetic mechanisms such as DNA 
methylation and histone modification. In fact, inhibition of DNA methylation and 
increased histone acetylation have neuroprotective effects in experimental models of 
stroke (Endres et al., 2000). Ischemic preconditioning induces substantial changes in 
acetylation of the H3 and H4 histones, which are associated with neuroprotection 
(Yildrim et al., 2008). These changes seem to facilitate widespread changes in 
transcription and support the concept of genomic reprogramming by preconditioning. 
Pharmacological inhibition of histone deacteylases with trichostatin A leads to increased 
histone acetylation and has a neuroprotective effect (Endres et al., 2000). Epigenetic 
mechanisms of gene regulation might therefore provide another avenue of therapeutic 
neuroprotection (Stenzel-Poore et al., 2003). Primarily through recent oligonucleotide-
based DNA microarray investigations and novel gene identification methods, the 
transcriptome of the ischemia-tolerant brain is gaining definition. Several themes are 
emerging from this work. First, genes representing many larger ‘families’ participate in 
the response — given the robustness of the protection in most tolerance models, this was 
not unexpected. Many share common promoter sequences that are responsive to 
preconditioning-activated transcription factors. On balance, genes functionally related to 
the cell cycle, metabolism, inflammation, excitotoxicity, ion homeostasis, signal 
transduction and so on are differentially expressed in response to preconditioning. 
Second, genes activated by preconditioning stimuli are often quite distinct from those 
associated with ischemia alone; similarly, the genomic expression pattern in response to 
ischemia is unique in a preconditioned animal, and differs considerably from the pattern 
activated by either preconditioning or ischemia in a non-preconditioned animal. Third, 
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although important and interesting from a cell survival standpoint, the genomic response 
is not simply one of activation of normally quiescent survival genes. Rather, gene 
repression also occurs, and, in fact, dominates the overall response to ischemia in a 
preconditioned brain. Finally, changes in gene transcription after preconditioning, or 
after ischemia in a preconditioned brain, have distinct temporal profiles. For example, 
following preconditioning, some genes are expressed or repressed within minutes or 
hours (adenosine A2a receptor and vascular endothelial growth factor (VEGF), whereas 
others are affected days later (β-actin, serine/threonine protein kinase, arachidonate 12-
lipoxygenase, calretinin, the S100A5 calcium-binding protein, dihydropyrimidine 
dehydrogenase and the zinc transporter ZnT1 (Stenzel-Poore et al., 2003; Tang et al., 
2006). At least three unique time windows of phenotypic, effector mechanism 
expression — that is, before, during and after ischemia — are worthy of closer 
examination. The first is the period of time that follows preconditioning but is prior to 
the lethal ischemic insult. At the cellular level, significant alterations in protein 
composition (such as elevations in the concentrations of various stress proteins, kinases 
and phosphatases, transcription factors, metabolic enzymes, transport and structural 
proteins, trophic factors and plasticity-related molecules, and cell cycle/apoptosis-related 
proteins) are underway or established prior to ischemia. These new protein signatures 
are representative of a tissue that is prepared to resist the threat of an impending 
ischemic event. The second window of effector mechanism expression relates to the 
period of ischemia itself, such that an identical insult is experienced as less severe in a 
preconditioned brain compared with a naive brain. In part, this occurs through increased 
inhibitory neurotransmitter levels, lower intra-ischemic levels of extracellular glutamate, 
reductions in calcium influx secondary to altered AMPA (α-amino-3-hydroxy-5-methyl-
4-isoxazole propionic acid) receptor subunit compositions, adenylation states, and 
desensitization status (Grabb et al., 2002; Dave et al., 2005).  
Pathophysiological events occurring during postischemic reperfusion are also 
positively modulated in ischemic tolerance. Effector mechanisms acting during this time 
window broadly serve to stabilize the cell’s energy and protein metabolism, ameliorate 
the actions of glutamate, reactive oxygen and nitrogen species and other injurious 
mediators, and reduce post-ischemic inflammation.  
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Tolerance mechanisms working at the level of endoplasmic reticulum function 
result in improved rates of recovery of neuronal protein synthesis; specifically, better 
preservation of the reinitiation and elongation steps of transcription, and increased levels 
of the chaperone glucose regulated protein 78 kDa (GRP78) are realized (Hayashi et al., 
2003). In addition, post-ischemic protein aggregation, redistribution and ubiquitin-
conjugation are reduced. The rate of repair of oxidative DNA damage is also enhanced. 
Overall, many facets of ischemic mitochondrial dysfunction, including changes in the 
redox activity of the respiratory chain components, oxidative phosphorylation deficits, 
calcium overload and the initiation of apoptosis, are abrogated in ischemic tolerance.  
Compared with the naive brain, the preconditioned brain also shows post-ischemic 
increases in the Mn and CuZn isoforms of superoxide dismutase (Bordet et al., 2000; 
Garnier et al., 2001), glutathione peroxidase and glutathione reductase, uric acid, and 
haeme oxygenase-1, which enhance the tissue’s free radical scavenging capabilities. 
Reductions in proinflammatory cytokine synthesis, and an upregulation of other 
feedback inhibitors of inflammation, including decoy receptors and intracellular 
signalling inhibitors, contribute to the promotion of an anti-inflammatory phenotype 
following ischemia. 
 
1.1.2 Clinical use: challenges and opportunities 
 
Ischemic brain injuries, resulting either from global or focal decreases in perfusion, are 
among the most common and important causes of disability and death worldwide. The 
consequences of global cerebral ischemia after cardiac arrest (and successful 
resuscitation), focal occlusions or disruption of brain vessels (ie, stroke, including 
subarachnoid haemorrhage and intraparenchymatous haemorrhage), and ischemic                                                                                     
brain damage after cardiac or brain surgery affect many millions of people in the USA 
alone. Research into preconditioning aims at developing new therapeutic approaches to 
benefit these patients. Preconditioning is an attractive experimental strategy to identify 
endogenous protective or regenerative mechanisms that can be therapeutically induced 
or supplemented. On the other hand, preconditioning could be used as a therapeutic 
technique by inducing tolerance in individuals in whom ischemic events are anticipated, 
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such as high-risk surgical cohorts or patients with subarachnoid haemorrhage or 
transient ischemic attack. Many articles have reviewed various features of ischemic 
preconditioning, tolerance, and endogenous neuroprotection in the brain (Dirnagl and 
Meisel, 2008).  
The options for inducing preconditioning and tolerance are not specific to the type of 
injury, which is important for the clinical adaptation of this technique. The table 1 gives 
an overview of the different types of preconditioning (cross, remote, immunological, 
pharmacological, anaesthetic, mimetic, and effectors).  
 
 
 
 
Table 1 Type of preconditionings. Adapted from Dirnagl et al, with permission from Elsevier. 
 
Preconditioning can protect the brain either almost immediately after stimulation 
(known as early, rapid, or classical preconditioning) or after a delay of 1 to 3 days to 
induce protein-synthesis-dependent protection (delayed preconditioning) (Ratan et al., 
2007). Most stimuli can cause both early and delayed preconditioning, and most, but not 
Dirnagl et al., Lancet Neurol 2009, 8: 398, 412. Table 1 
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all, stimuli leave an unprotected time window between early and delayed 
preconditioning (Ren et al., 2008). Irrespective of the rapidity of onset, protection by 
preconditioning usually never lasts more than a few days. Of note, a recent study 
showed that a series of repetitive hypoxic preconditioning stimuli can induce 
neuroprotection in the retina that last many weeks. Such long-term tolerance might be 
associated with neuronal plasticity, including long-term potentiation, or long-lasting 
cellular memory associated with immune tolerance. Rapid preconditioning is appealing 
practically and clinically because this technique can be applied therapeutically in the 
same setting as procedures with high risks of complication, such as cardiac or brain 
surgery. Most of the experimental and clinical research in cardiology has thus focused 
on early preconditioning. Conversely, because protection conferred by delayed 
preconditioning seems to be more robust for the brain than that conferred early, delayed 
preconditioning has received more attention in neurology. However, although there are 
effective protocols for early preconditioning for the brain, there are few formal 
comparisons of early and delayed procedures for neuroprotection (Perez-Pinzon, 2004). 
The recently described event of postconditioning is commonly discussed in the context 
of preconditioning. Postconditioning is a form of therapeutic reperfusion by which an 
organ is intermittently reperfused, for example by a stuttering opening and closing of an 
experimentally (or clinically, as in angioplasty or in organ transplantation) occluded 
artery. Postconditioning is a new neuroprotective approach for lessening injury in focal 
ischemia and reperfusion (Zhao, 2007). The benefits of this procedure seem to be 
mediated, at least in part, by molecular pathways similar to those that control 
preconditioning (Scartabelli et al., 2008; Pignataro et al., 2008). As an experimental 
strategy postconditioning, like preconditioning, might lead to the discovery of 
endogenous mechanisms of protection and repair. However, postconditioning is unlikely 
to be of clinical relevance as a therapeutic strategy for ischaemic brain damage (Dirnagl 
et al.;  2009). 
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2.1 Glutamate synthesis, release and uptake 
 
Glutamate is the major excitatory neurotransmitter in the mammalian central 
nervous system (CNS). In addition to its immediate impact as an excitatory amino acid, 
it has a role in long-term neuronal potentiation, as a proposed molecular substrate for 
learning and memory (Attwell, 2000; Meldrum, 2000; Tapiero et al., 2002; Tzschentke, 
2002). Glutamate may also be a potent neurotoxin, and glutamate excitotoxicity has 
been implicated in the pathogenesis of many devastating human neurological diseases 
such as stroke, amyotrophic lateral sclerosis (ALS) and epilepsy (Smith, 2000). It is 
found throughout the mammalian brain and participates in many metabolic pathways 
(Attwell, 2000; Petroff, 2002).  
Glutamine and α-ketoglutarate are thought to be the major precursors of glutamate, 
which is subsequently packaged into vesicles for future release into the synaptic cleft 
(Tapiero et al., 2002) (Fig. 3).  
 
 
 
Fig. 3  Synthesis and  metabolism of glutamate. 
 
Fig. 3 
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Glutamine is taken up into the pre-synaptic terminal via an active, Na+-dependent 
uptake protein (Anderson & Swanson, 2000; Daikhin & Yudkoff, 2000). It is then 
transported to mitochondria, where it is converted via phosphate activated glutaminase 
to glutamate and ammonia. α-ketoglutarate is also actively taken up into the pre-synaptic 
terminal, where it is transaminated into glutamate (Daikhin & Yudkoff, 2000). The 
glutamate in the terminal is then actively taken up into vesicles for future release. Upon 
release into the cleft, the glutamate either (i) is bound to pre- and post-synaptic 
receptors, (ii) is actively taken back up via a glutamate transporter and repackaged, (iii) 
diffuses away from the cleft, or (iv) is internalised by glial glutamate transporters 
(Anderson & Swanson, 2000; Attwell, 2000; Daikhin & Yudkoff, 2000) (Fig. 3).  
Five different mammalian glutamate transporters have been cloned (Attwell, 2000; 
Masson et al., 1999; Meldrum, 2000). Apart from cells in the retina and cerebellum, 
which express high levels of tissue-specific transporters, the transporters expressed most 
commonly throughout the brain are GLT-1/EAAT2 in glial cells and EAAC1/EAAT3 in 
neurons (Attwell, 2000; Masson et al., 1999; Smith, 2000). Once in glial cells, the 
glutamate is metabolised via glutamine synthase into glutamine or metabolised into α-
ketoglutarate by either glutamate oxaloacetate transaminase or glutamate dehydrogenase 
(Anderson & Swanson, 2000; Meldrum et al., 1999). This glutamine and α-ketoglutarate 
are then actively transported out of the glial cells and back into the pre-synaptic 
terminals for subsequent re-synthesis of glutamate (Meldrum et al., 1999). The 
extracellular concentration of glutamate is normally very low (≈1 µM) (Anderson & 
Swanson, 2000; Attwell, 2000) (see figure above).  
Glutamate is released from vesicles in pre-synaptic terminals by a Ca2+-dependent 
mechanism that involves voltage-dependent calcium channels (Anderson & Swanson, 
2000; Meldrum, 2000). The glutamate concentration within the vesicle is thought to be 
approximately 100 mmol/L; release of a single vesicle produces an excitatory post-
synaptic potential (EPSP) (Meldrum, 2000). Glutamate may also be ‘‘released’’ by 
reverse operation of the glutamate transporters (Anderson and Swanson, 2000). This will 
occur when the Na+ and K+ gradient across the membrane is reduced during cerebral 
ischemia (Meldrum, 2000).  
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The synaptic release of glutamate is controlled by a wide range of pre-synaptic 
receptors (Anderson & Swanson, 2000). These include not only the group II and group 
III metabotropic glutamate receptors but also cholinergic (nicotinic and muscarinic) 
receptors, adenosine (A1), κ-opioid, γ-aminobutyric acid (GABA)B, cholecystokinin and 
neuropeptide Y (Y2) receptors (Anderson & Swanson, 2000; Meldrum, 2000).  
Glutamate, like many other neurotransmitters, exerts its pleiotropic roles by means 
of multiple receptor proteins. Two main classes of glutamate receptors have been 
identified: ionotropic glutamate receptors (iGlus) and metabotropic glutamate receptors 
(mGlus), (Hollmann & Heinemann 1994; Nakanishi et al., 1998). 
 
2.2 Ionotropic glutamate receptors (iGluRs) 
 
Ionotropic glutamate receptors (iGluRs) are responsible for most fast excitatory 
signalling in the brain, and are thought to contribute to the synaptic plasticity that has 
been implicated in our ability to learn and form memories. In keeping with the 
physiological importance of iGluRs, their dysfunction is implicated in a range of 
neuropathologies, including epilepsy, stroke damage and the perception of pain 
(Dingledine et al., 1999).  
Pharmacologically distinct subfamilies of iGluR have been identified, 
characterized by their affinities for the synthetic agonists N-methyl-D-aspartate 
(NMDA), α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) and kainic 
acid (KA) (Hollmann et al., 1994).  
 
2.2.1 NMDA receptors 
  The NMDAR channel is made up of a combination of three different subunits, 
NR1– 3. When activated, the NMDAR allows the influx of cations, though most notably 
calcium. Excessive intracellular calcium concentrations cause the activation of 
intracellular pathways leading to both physiological (i.e. learning and memory) and 
pathological processes (i.e. excitotoxic injury). The NMDAR exhibits a complex gating 
mechanism, requiring not only binding of various ligands but also cellular 
depolarisation. The traditional NMDAR is heterotetramer composed of two NR1 
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subunits and two NR2 subunits. The NR1 subunit is made up of ~938 amino acids and 
has eight splice variants. Together, two NR1 subunits form the ion channel proper and 
exhibit all the classical properties attributed to NMDARs, including glutamate 
activation, magnesium block, zinc inactivation, glycine activation, interactions with 
polyamines and pH sensitivity (Fig. 4).  
 
 
In addition to glutamate binding, Mayer et al. (Mayer et al.; 1984) showed that 
depolarisation of the NMDAR-expressing neuron is necessary to electrostatically 
remove a magnesium ion normally blocking current entry at the level of the ion channel 
pore. Zinc can alternatively inhibit the NMDAR-mediated currents elicited by glutamate 
(Mayer et al.; 1989) (Fig. 5). Physiologically, magnesium is removed by the activation 
of other ionotropic glutamate channels (AMPA and kainate, to be discussed later). 
Glycine was shown by Johnson and Ascher (Johnson et al.;  1987) as a mandatory 
cofactor with glutamate necessary for NMDAR channel opening. The role of 
polyamines in NMDAR modulation is less clear and may participate in both cell growth 
and cell death. Spermine, a polyamine, can potentiate NMDAR currents at low 
concentrations, but also reduce currents in a voltage-dependent manner at higher 
concentrations (Rock, Macdonald; 1992). Spermine has also been shown to increase the 
frequency of channel opening and glycine affinity whilst acting as a voltage-gated 
NMDAR channel blocker when applied extracellularly (Benveniste and Mayer; 1993) 
To add to the complexity of the polyamine/NMDAR interaction, many of these effects 
Fig. 4 
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are dependent on the subunit constituents of the NMDAR channel (Williams, 1997) As 
such, the physiological significance of these interactions is still under investigation. 
 
 
 
Protons inhibit NMDAR current via a direct interaction with the NR1 subunit on a single 
lysine residue (Traynelis and Cull-Candy; 1990) which may be alleviated by spermidine 
and other polyamines (Ransom and Stec, 1988).  Physiologically, alterations in pH 
common after acute neurological insults (such as stroke and traumatic brain injuries) can 
modulate NMDAR function, but also other acid-sensing ion channels (ASICs, to be 
discussed later). NR2 subunits have more of a regulatory and refining role in NMDAR 
function. Currently, four NR2 subtypes exist (NR2A–D), with NR2A widely distributed 
in the brain, NR2B expressed primarily in the forebrain, NR2C found predominantly in 
the cerebellum and NR2D localised to the thalamus (Buller et al.; 1994). Within the 
Fig. 5 
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NMDAR complex, NR2 subunits modulate the characteristics of the NR1 ion channel 
pore mentioned above, though recently, NR2 subunits have been ascribed another role in 
postsynaptic architecture. Specifically, NR2B subunits have been shown to bind and link 
postsynaptic proteins, creating specialised postsynaptic microenvironments (Sattler et 
al.; 1999).  This close association is accomplished by postsynaptic densities comprising 
scaffolding proteins which allow the spatial approximation of intracellular enzymes (e.g. 
neuronal nitric oxide synthase) with ionic second messengers (e.g. Ca2+ influx from 
NMDARs). The physiological effect of this spatial relation can be dramatic and has been 
shown in animal studies to reduce histological damage as well as neurological 
dysfunction after stroke (Aarts et al.; 2002). Recent studies have shown a third subunit 
associated with the NMDA receptor gene family (Chatterton et al.; 2002). The NR3 
subunit is expressed in two isoforms: NR3A, which is expressed throughout the CNS, 
and NR3B, which is expressed primarily in motor neurons. Preliminary evidence 
suggests that NR1/NR3A and NR1/NR3B complexes are not activated by NMDA or 
glutamate, but rather elicit an excitatory Ca2+-impermeant response via glycine (Lau 
and Tymianski ; 2010). 
 
 
2.2.2 AMPA receptors 
The AMPA and kainate classes of glutamate receptors belong to the same 
superfamily as the NMDARs and share approximately 25% homology (Fig. 6).  
 
 
Fig. 6 
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AMPA receptors (AMPARs) are made up of a combination of four subunits 
(GluR1–4) and require only glutamate application for activation (Fig. 7).  
 
 
 
 
The specificity of cation influx of AMPARs is variable, however, and is governed 
primarily by subunit composition. GluR1, GluR3 and GluR4 all display strong inwardly 
rectifying current–voltage and calcium permeability, whereas the GluR2 subunit 
removes calcium permeability (Burnashev et al. 1995;  Geiger et al, 1995;  Hollmann et 
al, 1991).  
Physiologically, AMPARs are thought to regulate the fast excitation required to 
remove the magnesium block of nearby NMDARs. Kainate receptors are made up of 
subunits from GluR5–7 (also known as GluK5–7) and KA1–2 (also known as GluK1–
2). The properties of kainate channels are similar to AMPARs in that they allow ion flux 
directly following glutamate application, though they are mostly impermeant to calcium 
ions. Although AMPARs are localised mostly in the postsynaptic membrane, studies 
have shown that kainate receptors may be localised in both the presynapse (Chittajallu et 
al; 1996) and post-synapse (Castillo et al, 1997;  Vignes and Collingridge, 1997). Some 
studies have shown that the application of kainate can stimulate glutamate release 
(Schmitz et al.; 2001), whereas others have shown that kainate application inhibits 
presynaptic glutamate release (Frerking et al.; 2001). Postsynaptically, kainate channels 
serve a similar purpose as AMPARs in alleviating magnesium block in NMDARs (Lau 
and Tymianski; 2010).  
Fig. 7 
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2.3.1  Metabotropic glutamate receptors 
 
Metabotropic glutamate receptors (mGluRs) are single peptide seven-transmembrane 
spanning proteins linked to intracellular G-proteins (Fig. 8). It was originally believed 
that all 
metabotropic glutamate receptors used G-proteins as a transduction molecule, though 
recent evidence suggests that G-protein-independent signalling can occur (Heuss et a.; 
1999). Currently, eight different mGluRs (mGluR1–8) are known and are classified into 
three groups (groups I, II and III) based on sequence homology and their intracellular 
effects.
 
 
 
Fig. 8. Schematic representation of a homodimeric group I mGlu receptor stabilized by a disulfide bond. 
The large N-terminal extracellular domain (ECD) of each protomer consists of two globular ligand 
binding (LB1 and LB2) lobes linked by a hinge region where the agonist glutamate (Glu) binds. Agonists 
are thought to stabilize an active closed conformation by making contacts with residues of both lobes, 
whereas competitive antagonists bind at the same site as agonists but are unable to stabilize the active 
conformation. The ECD is connected to the seven-transmembrane domain (7TMD) by a cysteine-rich 
region. Gq proteins are associated with intracellular loops 2 and 3, whereas allosteric modulators (AMs) 
interact with TMD 6 and 7 (the coexisting tridimensional interaction with TMD 3 is not shown).  
Fig. 8 
Pellegrini-Giampietro D.E. Trends Pharmacol Sci 2003;24 (9):461-70. 
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a) Signal transduction mechanisms of group I mGlu receptors 
 
Group I mGlu receptors include mGlu1 and mGlu5 receptors and are coupled to 
phospholipase C (PLC) (Fig. 9).  
 
 
 
 
Fig. 5. Classification of metabotropic glutamate (mGlu)  receptors. The features of each mGlu receptor 
family group are shown. Greek letters are used for mGlu1a and mGlu1b splice variants, according to their 
original designation. Splice variants mGlu1c and mGlu4b are not included because data from different 
laboratories strongly suggest that they do not exist as full-length transcripts but probably represent 
recombination artifacts (F. Ferraguti, pers. commun.). Group I mGlu receptors are coupled to 
phospholipase C (PLC) via Gq proteins: their stimulation promotes the breakdown of phosphatidylinositol 
(4,5)-bisphosphate [PtdIns(4,5)P2] into inositol (1,4,5)-trisphosphate [Ins(1,4,5)P3] and diacylglycerol 
(DAG). Ins(1,4,5)P3 releases Ca2+ from intracellular stores, whereas DAG activates protein kinase C 
(PKC). Group II and III mGlu receptors are negatively coupled via Gi/o proteins to adenylyl cyclase (AC): 
their stimulation inhibits the formation of cAMP from its precursor ATP. 
Pellegrini-Giampietro D.E. Trends Pharmacol Sci 2003;24 (9):461-70. Fig. 9 
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PLC cleaves phosphatidylinositol-4,5-bisphosphate into inositol-1,4,5-trisphosphate 
(IP3) and diacylglycerol (DAG), which release Ca2+ from intracellular stores and 
activates PKC, respectively. Mobilization of intracellular Ca2+ in response to mGlu1 
receptor activation occurs through both the IP3 receptor and the ryanodine receptor 
present on the surface of the endoplasmic reticulum (del Río et al., 1999; Fagni et al., 
2000). It should be highlighted that activation of mGlu1 receptors can also increase 
intracellular Ca2+ concentrations through the opening of voltage sensitive calcium 
channels (VSCCs) and nonselective cation channels. In addition to the classical 
activation of PLC and release of Ca2+ from intracellular stores, stimulation of mGlu1 
and mGlu5 receptors can trigger a variety of signaling cascades and modulate the 
activity of ion and ligand-gated channels through functional coupling with other 
transduction pathways such as adenylyl cyclase, phospholipase A2, phospholipase D 
(Pellegrini-Giampietro et al., 2003), tyrosine kinase and mitogen-activate protein kinase.  
Activation of mGlu1 and mGlu5 receptors might thus promote multiple processes 
that are known to participate in the pathological cascade leading to post-ischemic 
neuronal death, including: (i) an increase in neuronal excitability caused by the 
activation of inward cationic currents or the reduction of  K+ conductances; (ii) a rise in 
cytosolic free Ca2+ via a facilitatory coupling between ryanodine receptors and L-type 
Ca2+ channels or direct Ca2+ influx from the extracellular space through NMDA 
receptors and L-type channels (Fagni et al., 2000); (iii) an enhancement of the release of 
glutamate that correlates with the neurotoxic effects of group I mGlu receptor agonists; 
(iv) a potentiation of NMDA and AMPA receptor responses that has been observed in a 
large number of brain areas; and (v) activation of the mitogen activated protein kinase 
pathway via PKC (Calabresi et al., 2001). 
 
 
b) Signal trasduction mechanisms og group II/III mGlu receptor 
 
Group II mGluRs include mGluR2s and mGluR3s. These mGluRs cause a decrease in 
adenylyl cyclase signalling, resulting in downstream inhibition of voltage-dependent 
calcium channels (Chavis et al., 1994; Tanabe et al., 1993). These receptors are found at 
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both the presynapse and the post-synapse (Ohishi et al.; 1994). Since presynaptic 
calcium is integral to neurotransmission, group II mGluRs modulate neurotransmission 
via their action on voltagegated calcium channels. Group III mGluRs include mGluR4s, 
mGluR6s, mGluR7s and mGluR8s. These mGluRs have similar properties to the group 
II mGluRs and are also associated with a decrease in adenylyl cyclase signalling, 
resulting in downstream inhibition of voltagedependent calcium channels (Tanabe et al., 
1993). These mGluRs are also found in both the presynaptic and postsynaptic terminals 
(Bradley et al.; 1996) and similar to group II receptors, these mGluRs modulate 
neurotransmission by functioning as autoreceptors and modulating calcium channel 
influxes. With respect to excitotoxicity, the group I family of mGluRs is associated with 
the post-synapse and appear to potentiate NMDAR-mediated Ca2+ influx (Bruno et al; 
1995). The remaining metabotropic glutamate receptor heterodimers comprising 
mGluR2,3 and mGluR4,6,7,8 subunits are linked to the inhibition of cAMP formation 
(see the figure above). These receptors are primarily found in the pre-synapse and 
reduce Ca2+ influx via NMDARs (Bruno et al.; 1995). The above evidence shows that 
alterations in the amino acid sequences of glutamate receptor subunits could alter 
calcium permeability or other properties which could lead to worsening excitotoxicity. 
However, whilst there are currently no known channelopathies attributable to glutamate 
receptor mutations directly, some recent evidence has suggested that mutations in 
postsynaptic proteins bound to AMPARs may exert a channelopathy-like effect in 
epilepsy (Fukata et al.; 2006). Improved knowledge of the pharmacology and 
distribution of glutamate receptors may also lead to the development of improved 
receptor antagonists for the treatment of neurologic disease. Finally, the linkage of 
ionotropic receptors to intracellular enzymes may provide alternative targets for 
pharmacological neuroprotection following excitotoxic insults (Lau and Tymianski; 
2010). 
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3.1 Structure and function of membrane associated guanylate kinase 
(MAGUK) proteins 
 
Neurotransmitter receptors at excitatory synapses are clustered at the postsynaptic 
density (PSD), an electrondense structure located beneath the postsynaptic membrane 
(Fig. 10). 
 
Fig. 10 Neurotransmitter receptors at excitatory synapses clustered at the postsynaptic density 
(PSD) and scaffold proteins. 
 
 The PSD also contains scaffolding proteins, the prototypical one being PSD-95 that is a 
member of the neuronal MAGUK family of proteins. The PSD-95-like subfamily of 
MAGUKs (PSDMAGUKs) includes PSD-93 (also known as Chapsyn-110), SAP-102 
and SAP-97 (Figure 1b,c). PSD-MAGUKs share a common domain structure 
organization with three N-terminal PDZ domains, a Src homology 3 (SH3) domain and a 
C-terminal catalytically inactive guanylate kinase (GK) domain. Despite these 
similarities in domain structure, PSD-MAGUKs are particularly distinct in their N-
terminal amino acid sequences. Furthermore, each PSD-MAGUK has several isoforms, 
Fig. 10 
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which differ in their N-terminal amino acid sequences and domain structure 
organizations. For example, whereas the N-terminal region of the a-isoforms of PSD-95 
and SAP-97 contain two cysteines that undergo palmitoylation, the bisoforms contain 
instead N-terminal L27 domains. Although PSD-MAGUKs are widely expressed 
throughout the central nervous system, the relative abundance of each PSD-MAGUK in 
specific brain regions varies with development. In the hippocampus, for example, SAP-
102 expression is high in late embryonic development and early postnatal life, and 
decreases with age. By contrast, the expression of PSD-95 and PSD-93 is low during 
early postnatal life but increases substantially by one month of age (Sans. et al. 2000). 
 Each member of MAGUK protein family is distributed differently in the brain 
cell compartments. PSD-95 and PSD-93 are highly enriched in the PSD, especially due 
to their high palmitoylation degree (El-Husseini et al., 2000). SAP102 and SAP97 are 
found in dendrites and axons and are abundant in the cytoplasm as well as at synapses. 
Although they show similar specificities of protein interaction in vitro, MAGUK family 
members interact with different (but overlapping) sets of proteins in vivo. The COOH-
terminal cytoplasmic tails of NR2 subunits of NMDA receptor directly interact, at least 
in vitro, with PDZ domains of all members of the MAGUK family (Kim and Sheng, 
2004). In particular, the last three amino acids of the carboxyl termini of NR2A and 
NR2B subunits have a C-terminal consensus motif threonine/serine-Xvaline (T/SXV, 
where X is any amino acid) that has been demonstrated to be responsible for efficient 
binding to PDZ domains of MAGUK protein members such as PSD-95 (Niethammer et 
al., 1996). PSD-95, in turn, binds to the amino terminal of neuronal nitric oxide synthase 
(nNOS), a Ca2+-activated form of nitric oxide synthase (NOS), through its PDZ 
domain. Therefore, PSD-95 may concentrate nNOS near the NMDA receptor at 
postsynaptic sites in neurons (Christopherson et al., 1999) thereby connecting NMDA 
receptors to specific signal transduction pathways (Kennedy, 1998). On the other hand, 
the interaction with SAP97 appears to be more relevant for processing alpha amino- 3-
hydroxy-5-methyl-4- isoxazole propionic acid (AMPA) receptor subunits (Rumbaugh et 
al., 2003; Mauceri et al., 2004) and NR2A subunits of NMDA receptors (Mauceri et al., 
2007), whereas SAP102 is crucial for driving NR2B complexes to spines (Sans et al., 
2003). Of relevance, modifications of MAGUK protein function in the glutamatergic 
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synapse have been recently described in several neurological disorders such as 
Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Ischemia, 
Schizophrenia and neuropathic pain. In particular, modifications of MAGUK proteins 
interactions with NMDA receptors regulatory subunits are a common event in several 
neurodegenerative disorders (Gardoni et al., 2006; Aarts et al., 2002). Thus, a better 
knowledge and understanding of MAGUK structure and function as well as of the 
molecular events regulating MAGUK-mediated interactions in the glutamatergic 
synapse could lead to the identification of new targets for pharmaceutical intervention in 
neurodegenerative disorders. 
 
3.2 Modulation of PSD-95 interaction with NR2B subunit as a possible 
stroke treatment 
 
Neuronal injury caused by cerebral ischemia is believed to be mediated by excessive 
activation of glutamate receptors. Most of the studies focused on ischemia-induced 
changes in NMDA receptor complex in the postsynaptic density structure because of its 
temporal and spatial proximity to the initial events, which occur after an ischemic 
challenge. Changes in the composition and morphology of forebrain postsynaptic 
density have been reported to occur after an ischemic challenge. In addition, molecular 
interactions involving PSD-95 are modified by an ischemic challenge, in the most 
vulnerable CA1 region of the hippocampus. Ischemia also resulted in a decrease in the 
size of protein complexes containing PSD-95, but had only a small effect on the size 
distribution of complexes containing the NMDA receptor, indicating that molecular 
interactions involving PSD-95 and the NMDA receptor are modified by an ischemic 
challenge (Takagi et al., 2000). In addition, transient cerebral ischemia increases 
tyrosine phosphorylation of NMDA receptor subunits NR2A and NR2B, but has no 
effect on the amounts of individual NMDA receptor subunits in the postsynaptic density. 
The ischemia-induced increase in the interaction of NR2A and NR2B with the SH2 
domains of Src and Fyn suggests a possible mechanism for the recruitment of signalling 
proteins to the synapse and may contribute to altered signal transduction in the post-
ischemic hippocampus. Of great relevance, recent studies suggested to treat stroke 
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transducing neurons with peptides able to disrupt the interaction of NMDA receptor 
NR2B subunits with the postsynaptic density protein PSD-95 (Aarts et al., 2002). This 
procedure dissociated NMDA receptors from downstream neurotoxic signalling without 
blocking synaptic activity or calcium influx and protected cultured neurons from 
excitotoxicity, reducing focal ischemic brain damage in rats, and improved their 
neurological function. 
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4. Poly (ADP-ribose) polymerase and 
Poly (ADP-rybosil)ation 
 
 
 
 
 
 
 
 
 
 
 
 36 
4.1  The PARP superfamily 
 
Poly(ADP-ribose) polymerase-1 (PARP-1) also known as poly(ADP-ribose) synthetase 
and poly(ADP-ribose) transferase, is a nuclear enzyme present in eukaryotes. PARP-1 is 
a 116-kDa protein consisting of three main domains: the N-terminal DNA binding 
domain containing two zinc fingers, the automodification domain, and the C-terminal 
catalytic domain (Mazen et al., 1989; de Murcia and Menissier de Murcia, 1994; de 
Murcia et al., 1994; Schreiber et al., 1995; Smith, 2001) (Fig. 11). The primary structure 
of the enzyme is highly conserved in eukaryotes (human and mouse enzyme have 92% 
homology at the level of amino acid sequence) with the catalytic domain showing the 
highest degree of homology between different species; the catalytic domain contains the 
so-called PARP signature sequence, a 50-amino acid block showing 100% homology 
between vertebrates (Fig. 12). 
 
 
Moroni F., Current Opinion in Pharmacology 2008, 8:96–103 
 
 
Fig.11 Schematic representation of PARP-1 domains. First, the amino (N)-terminal DNA-binding domain 
contains two zinc fingers, which are responsible for DNA binding and DNA-damage-induced PARP 
activation. NLS is a nuclear-localization signal. Second, the automodification domain is a central 
regulating segment with a breast cancer-susceptibility protein-carboxy (C) terminus (BRCT) motif, which 
is common in many DNA repair and cell cycle proteins. Third, the C-terminal domain contains the NAD-
binding region and the catalytic center of PARP 
 
 
PARP-2 (62 kDa) is the second member of the family and was discovered as a 
result of the presence of residual 10– 15% PARP activity in fibroblast derived from 
PARP-1- deficient mice. Although PARP-2 DNA-binding domain consists of only 64 
amino acids and lacks any obvious similarity with the corresponding PARP-1 domain, 
Fig. 11 
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the catalytic and automodification domains display significant similarity. PARP-2, 
similarly to PARP-1, is activated by DNA-strand interruptions and contributes to the 
maintenance of genomic stability. The two proteins probably display redundant 
functions because Parp-1 and Parp-2 double gene disruption is lethal to embryos.  
PARP-3 (60 kDa) has a molecular structure rather similar to PARP-2; it is mostly 
localized in the centrosome and its function is related to cell cycle transition [7]. The 
enzyme is almost absent in the brain. 
PARP-4 (193 kDa) is the largest member of the family and was originally 
identified as a component of the vaults (hence vPARP). These are large 
ribonucleoprotein particles (three times the dimension of a ribosome) located in cell 
cytoplasm and are named after their shape reminiscent the vaulting in a cathedral. It has 
been proposed that these particles are involved in cellulartransport and are associated 
with multidrug resistance to anticancer drugs. 
PARP-5 (142 kDa) was only recently identified and because it is a partner of the 
human telomeric protein TRF1 was named Tankyrase 1 (TRF1-interacting, ankyrin-
related ADP-ribose polymerase) and its main function is probably related to the 
maintenance of telomere length. Experiments with siRNA showed that the enzyme 
contributes in the assembly of bipolar spindles: a decrease of its expression causes 
mitotic arrest with the appearance of abnormal mitosis. 
PARP-10 is a partner of the proto-oncoprotein c-Myc, a key transcriptional 
regulator that controls cell proliferation. PARP-10 contains an RNA recognition motif 
(RRM) and a Gly-rich domain, both of which have also been found mediating RNA 
binding in a c-Myc nucleolar partner protein-nucleolin. PARP-10 shuttles between the 
cytoplasm and the nucleus and accumulates within the nucleolus where it acquires a 
CDK2-dependent phosphorylation during late-G1–S phase and during prometaphase to 
cytokinesis39. PARP-10 is a potent inhibitor of the cell transformation that is mediated 
by c-Myc in the presence of Ha-Ras, but its PARP activity is not required8. PARP-10 
could counteract some nucleolar  c-Myc functions that promote cellular transformation. 
Furthermore, PARP-10 poly(ADP-ribosyl)ates histone H2A, which indicates that it has a 
role in chromatin regulation. 
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No known domains have been found in PARP-6, PARP-8, PARP-11 and PARP-
16 so far (except a WWE domain in PARP-11), which makes it difficult to speculate on 
their possible functions (Moroni F; 2008). 
 
Schreiber et al., (2006)  Nat Rev Mol Cell Biol. 7(7):517-28.  
 
Fig. 12 The PARP superfamily. The domain architecture of the 17 members of the poly(ADP-ribose) 
polymerase (PARP) superfamily and of poly(ADP-ribose) glycohydrolase (PARG). Protein domains that 
are illustrated by coloured boxes were defined according to the Pfam 19.0 or CCD v2.06 (National Center 
for Biotechnology Information) databases.  
Fig. 12 
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4.2 Function of PARPs 
 
PARP is a family of nuclear enzymes involved firstly in DNA repair operating as sensor 
of DNA damage and signalling molecule binding to both single- and double-stranded 
DNA breaks. Upon binding to damaged DNA mainly through the second zinc-finger 
domain, PARP-1 forms homodimers and catalyzes the cleavage of NAD+ into 
nicotinamide and ADP-ribose and then uses the latter to synthesize branched nucleic 
acid-like polymers poly(ADP-ribose) covalently attached to nuclear acceptor proteins 
(de Murcia et al., 1994; de Murcia and Menissier de Murcia, 1994; Lindahl et al., 1995; 
Schreiber et al., 1995; Burkle, 2001; Smith, 2001) (Fig. 13).  
 
Fig. 13 Metabolism of poly(ADP-ribose) during DNA damage and repair. 
 
The size of  the branched polymer varies from a few to 200 ADPribose units. Because of 
its high negative charge, the covalently attached ADP-ribose polymer dramatically 
affects the function of target proteins. Poly-ADP ribosylation is a dynamic process, 
indicated by the short (∼1 min) in vivo half-life of the polymer (Whitacre et al., 1995). 
Two enzymes—poly(ADP-ribose) glycohydrolase (PARG) and ADP-ribosyl protein 
lyase—are involved in the catabolism of poly(ADP-ribose), with PARG cleaving ribose-
ribose bonds of both linear and branched portions of poly(ADP-ribose) and the lyase 
removing the protein proximal ADP-ribose monomer (Davidovic et al., 2001). The 
Fig. 13 
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regulation of PARP-1 activity is established through different mechanisms. The best 
characterized mechanism is the down-regulation of enzyme activity through auto-poly-
ADP-ribosylation (Kawaichi et al., 1981). Furthermore, nicotinamide, the smaller 
cleavage product of NAD_, also exerts inhibitory effect on PARP-1, allowing negative 
feedback regulation. Recently, the purines hypoxanthine, inosine, and adenosine also 
were identified as another class of endogenous PARP inhibitors (Virag and Szabo, 
2001). Phosphorylation of PARP by protein kinase C also results in enzyme inhibition 
(Tanaka et al., 1987; Bauer et al., 1992). The abundance of PARP may also change 
under certain conditions, suggesting a transcriptional or posttranscriptional regulation 
(Bergeron et al., 1997; Tramontano et al., 2000; Doucet-Chabeaud et al., 2001). The 
physiological or pathophysiological relevance of this pathway is poorly understood at 
present. The biological role of poly(ADP-ribose) is complex and involves main 
functions: 
I) PARP-1 has been implicated in DNA repair and maintenance of genomic 
integrity (de Murcia and Menissier de Murcia, 1994; de Murcia et al., 1994,1997; 
Schreiber et al., 1995; Chatterjee et al., 1999b; Shall and de Murcia, 2000). This 
“guardian angel” function is indicated by delayed DNA base-excision repair and by a 
high frequency of sister chromatid exchange in PARP-1-deficient cells exposed to 
ionizing radiation or treated with alkylating agents (de Murcia et al., 1997). High levels 
of ionizing radiation and alkylating agents elicit higher lethality in PARP-1- deficient 
mice when compared with wild-type ones (de Murcia et al., 1997).  
II) PARP-1 also regulates the expression of various proteins at the 
transcriptional level. Of special importance is the regulation by PARP-1 of the 
production of inflammatory mediators such as the inducible nitricoxide synthase (iNOS) 
(Hauschildt et al., 1992; Le Page et al., 1998; Szabo et al., 1998c; Oliver et al., 1999), 
intercellular adhesion molecule 1 (ICAM-1) (Zingarelli et al., 1998; Szabo et al., 2001b), 
and major histocompatibility complex class II (Otsuka et al., 1991). NF-kB is a key 
transcription factor in the regulation of this set of proteins, and PARP has been shown to 
act as a coactivator in the NF-kB-mediated transcription (Oliver et al., 1999) (Fig. 14).  
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    A. Chiarugi, TIPS 23:122, 2002 
Fig. 14 Schematic representation of the ‘transcriptional hypothesis’. The balance between 
survival and death signals is finely tuned at the level of transcription. Several lines of evidence 
demonstrate an intricate relationship between the transcription factors p53 and nuclear factor 
κB (NF-κB) in both induction and execution of apoptosis. In particular, NF-κB activation by 
the RAF–MEK1–pp90rsk pathway seems essential in the p53-triggered death program. NF-κB 
also trans-activates p53, leading to the initiation of an apoptotic, vicious cycle. Intriguingly, 
poly(ADP-ribose) polymerase 1 (PARP-1) promotes both p53 and NF-κB activation. 
Therefore, the Ca2+-activated or DNA-damage-triggered poly(ADP-ribosyl)ation might 
regulate cell death as a key modulator of the deadly p53–NF-κB system. NF-κB activation is 
also central in the inflammatory response. Thus, it is conceivable that the pro-inflammatory 
effects of PARP-1 might be attributed to the facilitation of NF-κB-driven transcription. 
Abbreviations: Ins(1,4,5)P3, inositol (1,4,5)-triphosphate; MEK, mitogen-activated protein 
kinase kinase; PLC, phospholipase C. 
 
Poly(ADP-ribosylation) of histones may also contribute to the transcription-
promoting effect of PARP-1, because poly(ADP-ribose) confers negative charge to 
histones, leading to electrostatic repulsion between histones and DNA. Thus, poly(ADP-
ribosylation) can loosen the chromatin structure and can thereby make genes more 
Fig. 14 
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accessible for the transcriptional machinery. Nuclear receptor-mediated transcription is 
regulated by PARP-1 in a different manner: PARP-1 seems to suppress nuclear receptor-
mediated transcription (Miyamoto et al., 1999).  
III) PARP-1 regulates replication and differentiation. The involvement of 
PARP-1 in the regulation of replication is supported by observations that 
poly(ADPribose) metabolism is accelerated in the nuclei of proliferating cells (Tanuma 
et al., 1978; Kanai et al., 1981; Leduc et al., 1988; Bakondi et al., 2002a). Furthermore, 
PARP-1 is part of the multiprotein replication complex (MRC) (Simbulan-Rosenthal et 
al., 1996), indicated by copurification of PARP-1 with key components of MRC 
(Simbulan-Rosenthal et al., 1996; Dantzer et al., 1998). Moreover, several replication 
factors and centromere proteins have been shown to serve as substrates for PARP 
(Simbulan-Rosenthal et al., 1996; Saxena et al., 2002). Another mechanism by which 
PARP may regulate nuclear processes is poly(ADP-ribosylation) of histones facilitating 
the assembly and deposition of histone complexes on DNA during replication (Boulikas, 
1990).  
IV) Poly(ADP ribosylation) has been implicated in the regulation of telomerase 
activity. The overexpression of tankyrase-1, a recently discovered PARP enzyme, in 
telomerase-positive human cells resulted in a gradual and progressive elongation of 
telomeres (Smith and de Lange, 2000). Besides tankyrase-1, PARP-1 has also been 
implicated in the maintenance of telomere length. Genetic ablation of PARP-1 has been 
shown to result in telomere shortening (d’Adda di Fagagna et al., 1999) but others found 
no difference in telomere length of PARP-proficient and –deficient cells (Samper et al., 
2001).  
V) PARP-1 activation has been proposed to represent a cell-elimination pathway 
(Berger et al., 1983, Schraufstatter et al., 1986b; Sims and Benjamin, 1987; Schreiber et 
al., 1995; Kleczkowska and Althaus, 1996) through which severely damaged cells are 
removed from tissues. PARP-1-mediated cell death occurs in the form of necrosis 
(Schreiber et al., 1995; Virag et al., 1998a,b), which is probably the least desirable form 
of cell death. During necrotic cell death, the cellular content is released into the tissue, 
exposing neighboring cells to potentially harmful attacks by proteases and other released 
factors. This scenario is best exemplified by cells that have been exposed to DNA-
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damaging stimuli. Mild genotoxic noxa cause PARP activation that facilitates DNA 
repair and cell survival. Severe DNA damage, however, causes overactivation of PAR,P 
resulting in the depletion of NAD_ and ATP and consequently in necrotic cell death.  
VI) Poly(ADP-ribose) polymer has been identified recently as an emergency 
source of energy used by the base-excision machinery to synthesize ATP (Maruta et al., 
1997; Oei and Ziegler, 2000).  
VII) Similarly to ubiquitination, poly(ADP-ribose) may also serve as a signal for 
protein degradation in oxidatively injured cells (Ullrich and Grune, 2001; Ullrich et al., 
2001a). Hydrogen-peroxide treatment of K562 cells caused a PARP-1-dependent up-
regulation of 20S proteosome activity. During this process, the proteosome becomes 
poly(ADP-ribosylated), resulting in the enhanced degradation of poly(ADP-ribosylated) 
histones (Ullrich and Grune, 2001). Immunoprecipitation experiments demonstrated a 
protein-protein interaction of the functionally active PARP with the proteasome in 
correlation with the proteasome activity (Ullrich et al., 2001a).  
VIII) In addition to PARP-catalyzed covalent poly-(ADP-ribosylation), 
poly(ADP-ribose) polymers can noncovalently bind to specific (ADP-ribose)n binding 
motifs in proteins, such as histones, XRCC1, p53, and DNA polymerase _, and thereby 
modify their function (Althaus et al., 1993; Pleschke et al., 2000). Such (ADPribose) 
polymers can be formed during the catabolism of poly(ADP-ribose) by poly(ADP-
ribose) glycohydrolase (Davidovic et al., 2001). 
 In the IX and final function, poly(ADP-ribosylation) may also be involved in the 
regulation of cytoskeletal organization. A recent study reported morphological 
alterations in Drosophila overexpressing PARP-1 (Uchida et al., 2001). The 
overexpression of PARP-1 disrupted the organization of cytoskeletal F-actin, resulting in 
aberrant cell and tissue morphology. Furthermore, heat-induced PARP expression 
disrupts the organization of cytoskeletal F-actin in embryos and tissue polarity in adult 
flies. Whether these morphological alterations are indeed related to PARP-1 function or, 
alternatively, whether PARP-1 overexpression interferes with the function of 
cytoplasmic PARP enzymes remains to be seen.  
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4.3 Poly(ADP-ribosyl)ation and stroke 
 
It has now clearly established that neuronal death following stroke is mainly due to a 
cascade of events originating from massive release of the excitatory neurotransmitter 
glutamate. Subsequent over-activation of neuronal glutamate receptors prompts de-
regulation of ionic fluxes through the plasma membrane with persistent intracellular 
Ca2+ accumulation in neurons. This in turn causes a prolonged and non-specific 
activation of numerous enzymes such as proteases, lipases and nucleases which results 
in excitotoxic neuronal death (Lipton et al.; 1994). Ischemic neuronal death is mediated, 
at least in part, by augmentation of nitric oxide (NO) caused by NMDA receptor-
dependent activation of neuronal NO synthase (nNOS) activity. PARP-1 hyperactivity is 
causative in post-ischemic brain damage. In the intricate cascade of events that leads to 
ischemic neurodegeneration, PARP-1 is thought to be localized downstream to DNA 
damage induced by reactive oxygen and nitrogen species. Several lines of evidence 
support this assumption. For instance, using the comet assay to evaluate single and 
double strand DNA breaks, it has been demonstrated that NMDA receptor antagonists 
reduce DNA ruptures and ischemic brain injury, whereas PARP-1 inhibitors decrease 
infarct volumes without reducing the extent of DNA damage (Giovannelli et al.; 2002). 
Furthermore, PARP-1 activation is significantly reduced in the ischemic brain of mice 
deficient in nNOS (Endres et al.; 1998), and PAR formation is diminished in the 
ischemic cortex of rats receiving the nNOS inhibitor 7-nitroindazole (Tokime et al.; 
1998). However, PARP-1-null mice are less sensitive to ischemia than those nNOS−/− 
(Skaper et al.; 2003), suggesting that mechanisms in addition to NO concur to PARP- 1 
activation. Hyperactivation of PARP-1 in the ischemic brain is not a single, time-limited 
event in the complex and prolonged process of ischemic neuronal death. Indeed, a 
vicious cycle triggered by intraneuronal Ca2+ accumulation leads to multiple waves of 
reactive oxygen species (ROS) formation in the ischemic brain tissue (Pellegrini-
Giampietro et al.; 2003), thereby eliciting prolonged DNA damage and sustained PAR 
formation. The latter can also be due to self-amplifying positive forward cycles of 
ischemia-induced immune cell recruitment and ROS production (Szabo et al.; 1997), 
and/or to direct Ca2+-dependent PARP-1 activation (Homburg et al.; 2000). Consistent 
with PARP-1 recruitment in ischemic brain damage, enzymatic activity of PARP-1 in 
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gerbils subjected to transient (5 min) global ischemia increases in the injured tissue 4.3- 
and 1.7-fold at 1 and 24 h of reperfusion, respectively (Nagayama et al.; 2000). 
Prolonging duration of ischemia (10 min) leads to significant increases of PARP-1 
activity up to the seventh day of reperfusion (Strosznajder et al.; 2003). In a focal and 
transient model of brain ischemia [2 h middle cerebral artery occlusion (MCAo) and 2 h 
reperfusion] in mice, PAR formation is highly increased in the nuclei of cells of cerebral 
cortex compared to those present in the contralateral one. Of note, polymer formation is 
drastically decreased both in the ischemic and contralateral cortex of PARP-1−/− mice 
subjected to MCAo (Eliasson et al.; 1997). A parallel study in mice reports that 
following 2 h MCAo increased PAR formation in the ischemic cortex occurs as early as 
5 min after reperfusion in cells showing swelling and nuclear disruption (Endres et al.; 
1997) PAR accumulation, however, is not evident at later times (3–6 h) of reperfusion or 
after milder ischemic insult (1 h MCAo) (Endres et al.; 1997). PAR formation has also 
been investigated in a permanent model of MCAo in rats. Authors report that PAR 
immunoreactivity increases in the ischemic core and penumbra 2–8 h after ischemia, 
returning to basal levels 16 h post-ischemia. Importantly, PAR immunoreactive cells of 
the ischemic cortex show the classical morphology of pyramidal neurons (Tokime et al.; 
1998).. Similarly, the ischemic cortex of rats subjected to distal MCAo and transient 
bilateral common carotid artery occlusion have a 3-fold increase of PAR 
immunoreactive cells 10 min after 1.5 h ischemia. Remarkably, PAR formation also 
occurs in neural cells of the infarcted human brain at 18–24 post-insult and rapidly 
declines, thereafter. A second wave of poly(ADP-ribosyl)ation is due to PAR-positive 
macrophages which start infiltrating the ischemic human brain 3 days after the ischemic 
injury (Love et al.; 2000). In a subsequent study in humans it is reported that brain 
ischemia causes accumulation of PAR in the ischemic core and penumbra mostly during 
the first 2 days after cardiac arrest. Remarkably, double immunostaining for PAR and 
the neuronal marker MAP2 indicates that the majority of PAR-positive cells are neurons 
(Love et al.; 1999). It has also been reported that brain ischemia alters PARP- 1 
expression levels. For example, Love and colleagues show that expression of PARP-1 
increases in the infarcted tissue of the human brain 18–24 h post-insult and, similarly to 
PAR, declines thereafter (Love et al.; 2000). Accordingly, a classic study on PARP-1 
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and excitotoxic neuronal death reports that PARP-1 protein as well as its mRNA levels 
increase in the nucleus of cultured cerebellar granular cells upon exposure to neurotoxic 
concentrations of glutamate (Cosi et al.; 1994). Indeed, the group of Sharp reports an 
increase of PARP-1 mRNA in the dentate gyrus of gerbil brains 4 h after 10 min of 
global ischemia and return to basal levels 8 h after ischemia (Liu J et al.; 2000). 
Conversely, Nagayama and associates (Nagayama et al.; 2000) as well as Strosznajder 
and colleagues (Strosznajder et al.; 2003) show that PARP-1 mRNA and protein do not 
increase in the gerbil hippocampus in the same ischemia model. These results taken 
together unambiguously establish a central role of cerebral ischemia in altering the 
homeostasis of poly(ADP-ribosyl)ation in neurons of different species including 
humans. 
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5. Histone deacetylases and  
Histone acetyl transferases 
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The histones are highly alkaline proteins found in eukaryotic cell nuclei, which package 
and order the DNA into structural units called nucleosomes. They are the chief protein 
components of chromatin, act as spools around which DNA winds, and play a role in 
gene regulation. Histones "are highly conserved and can be grouped into five major 
classes: H1/H5, H2A, H2B, H3, and H4". These are organized into two super-classes as 
follows: 
• core histones – H2A, H2B, H3 and H4  
• linker histones – H1 and H5  
Two of each of the core histones assemble to form one octameric nucleosome core (Fig. 
15).  
 
Fig. 15 Core histones assemble to form one octameric nucleosome core around 
which the DNA is rolled up. 
 
The assembled histones and DNA is called chromatin. The nucleosome core is formed 
of two H2A-H2B dimers and a H3-H4 tetramer, forming two nearly symmetrical halves 
by tertiary structure.  The 4 'core' histones (H2A, H2B, H3 and H4) are relatively similar 
in structure and are highly conserved through evolution. Histones are subject to post 
translational modification by enzymes primarily on their N-terminal tails, but also in 
their globular domains. Such modifications include methylation, citrullination, 
acetylation, phosphorylation, SUMOylation, ubiquitination, and ADP-ribosylation. This 
Fig. 15 
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affects their function of gene regulation. In particular, protein acetylation is dynamic and 
maintained by two classes of functionally antagonistic enzymes: the protein acetylases 
and the deacetylases (Kouzarides; 2007) (Fig. 16). Levels of histone acetylation depend 
on the activities of histone acetylases (HATs) and HDACs, which add or remove acetyl 
groups from protein substrates, respectively (Sun et al.; 2003). 
        Although transcriptional regulation is highly complex and dynamic, in general an 
increase in histone acetylation causes remodelling of chromatin from a tightly packed 
configuration to a loosely packed configuration, which subsequently leads to 
transcriptional activation. Conversely, a decrease in histone acetylation may cause 
chromatin structure to condense and result in transcriptional silencing. So, upregulation 
of transcription can be achieved in cells either by stimulation of HAT or by inhibition of 
HDAC activities, and the opposite is true for transcriptional downregulation. In addition 
to modification of histones, other (nonhistone) cellular proteins are substrates for 
HDACs, and these proteins mediate diverse biological functions via transcriptional-
dependent as well as independent mechanisms (Zhang. et al., 2003;  Bolden et al., 
2006). In fact, phylogenetic analysis of bacterial HDAC relatives suggests that 
evolutionary development of modern HDACs preceded the evolution of histone proteins, 
and raises the possibility that the primary activity of some HDACs is directed against 
non-histone substrates (Gregoretti et al.; 2004). 
 
 
 
Fig. 16 a) Levels of histone acetylation at specific lysine (K) residues determinet by concurrent reaction of 
acetylation and deacetylation mediated by histone acetylases (HAT) and histone deacetylases (HDACs) b) HDAC 
inhibitors block the hitone acetylation level s, leading to an increased acetylation, chromatin modification to relax 
conformation and transcription upregulation.   
Fig. 16 Kazantsev AG, Thompson LM. Nat Rev Drug Discov. 2008 Oct;7(10):854-
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5.1 Structure–function analysis of human HDACs 
 
The superfamily of HDACs consists of five main subtypes: classes I, IIa and IIb, and IV, 
and the structurally distinct class III (Gregoretti et al., 2004; Butler et al., 2006) (Fig. 
17).  
Class I and class II HDACs include the Zn2+-dependent deacetylases, which 
share significant structural homology, especially within the highly conserved catalytic 
domains (Thiagalingam et al., 2003; Wang et al., 2004). Class I HDACs contain the 
ubiquitously expressed HDAC1, HDAC2 and HDAC3, and the muscle-specific 
HDAC8. HDAC1 and HDAC2 are predominantly localized in the nucleus, whereas 
HDAC3 shuttles between the nucleus and cytoplasm (Fig. below). All three of these 
deacetylases contain a nuclear localization signal within their protein sequences, and 
HDAC3 additionally has a nuclear export signal (Yang et al.; 2002).  
Class IIa HDACs consist of four members — HDAC4, HDAC5, HDAC7 and HDAC9 
— with distinct tissue specific patterns of expression, predominantly in muscle and heart 
(Martin et al., 2007;  Majdzadeh et al.; 2008). These proteins contain extended amino-
terminal domains of ~600 amino acids, which mediate interactions with HDAC3, 
myocyte enhancer factor 2 (MeF2), repressor complex NCoR2/SMRT and 14-3-3 
proteins, followed by the Zn2+-containing catalytic domain. MITR — an amino-terminal 
splice variant of HDAC9 lacking the catalytic domain — HDAC4 and HDAC5 interact 
with heterochromatin protein 1 (HP1). HP1 is an adaptor protein that recognizes histone 
methylated lysines and mediates transcriptional repression by recruiting histone 
methyltransferases (Zhang et al.; 2002). Interestingly, some data indicate that HDAC4, 
HDAC5 and HDAC7 are unable to deacetylate histones themselves, but probably 
participate in gene-specific transcriptional regulation via an interaction with class I 
HDAC3 (Wen et al.; 2000; Fischle et al.; 2001). However, new results have 
demonstrated intrinsic deacetylase activity of HDAC4 and other class IIa deacetylases, 
and have showed that these enzymes are particularly active on class IIa-specific 
substrates in vitro (Lahm et al., 2007; Jones et al., 2008). This suggests that vertebrate 
class IIa HDACs may have evolved to maintain low basal activities on acetyl-lysines 
and to efficiently process restricted sets of specific, still undefined, natural substrates 
(Lahm et al., 2007). HDAC4, HDAC5, HDAC7 and MITR shuttle between the nucleus 
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and cytoplasm, whereas full-length HDAC9 is localized in the nucleus (Wang & Yang, 
2001; Petrie et al.; 2003).  
Class IIb HDACs include HDAC6 and HDAC10. The structure of HDAC6 is 
unusual in that it contains two independently functioning catalytic domains and a 
carboxy-terminal Zn2+-finger ubiquitin binding domain (Bertos et al.; 2001). HDAC6 
functions in the cytoplasm where it deacetylates a-tubulin and alters microtubule 
stability (Hubbert  et., 2002; Matsuyama et al., 2002). Its close structural homologue 
HDAC10 lacks the second functional catalytic domain (Tong et al., 2002). HDAC10 has 
been found in a complex with HDAC3, although the exact functions of this deacetylase 
are not known. 
The class IV enzyme HDAC11 is structurally different from the class I and class 
II deacetylases. HDAC11 is predominantly localized in the nucleus; however it 
coprecipitates with the primarily cytosolic HDAC6 (Gao et al.; 2002). The function of 
this deacetylase is poorly understood, although region-specific and developmental 
expression patterns have been observed in the mouse brain (Liu et al.; 2008). By 
contrast, the class III deacetylases, or sirtuins, are structurally and functionally different 
from other HDACs. 
Named after the silent information regulator 2 (Sir2) gene — the first sirtuin identified 
in budding yeast — in humans, the class III HDACs include seven members (Michan & 
Sinclair 2007; Gan et al.; 2008). Sirtuins are markedly different in their absolute 
dependence on NAD+ to carry out catalytic reactions, which include both deacetylase 
and mono-ADP-transferase activities (Sauve et al.; 2006). The predominant deacetylase 
activity has been shown for the class III HDACs SIRT1, SIRT2, SIRT3 and SIRT5 (Gan 
et al., 2008; North et al.; 2005). The deacetylation reaction mediated by sirtuins is 
coupled to the cleavage of NAD+, yielding nicotinamide and 2′-O-acetyl ADP-ribose, 
along with the deacetylated lysine residue within the protein substrate54. Structurally, 
human SIRT1 is the closest analogue of yeast Sir2, which regulates cellular metabolism 
and ageing (Michan. & Sinclair 2007). SIRT2 has both nuclear and cytosolic 
localization, and interacts with numerous protein partners to execute multiple functions 
in cells. SIRT1 deacetylates a single lysine residue on several histones: K16 on histone 4 
(H4), K14 on histone 3 (H3) and K26 on histone 1 (H1). Non-histone substrates of 
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SIRT1 include the transcription factors p53, TAFI68, p300 and peroxisome 
proliferatoractivated receptor-g, coactivator 1a (PGC1a). SIRT2 is a cytosolic protein 
that deacetylates a-tubulin and microtubules, a function that is redundant with that of 
HDAC6 (North et al., 2005; Southwood et al.; 2007). Subsequently, it has been shown 
that SIRT2 also deacetylates K16 on H4 (Vaquero et al.; 2006) and localizes to neuronal 
nuclei. SIRT3, which shares the most structural similarity with SIRT2, is a 
mitochondrial protein. Acetyl-CoA synthetase (ACS2) has been identified as a SIRT3 
substrate; however other data suggest a broad role for SIRT3 in regulating global 
mitochondrial lysine acetylation (Schwer et al., 2002; Hallows et al., 2006). 
Mitochondrial subcellular localization has also been suggested for SIRT5 (Michishita et 
al.; 2005), but the function of this protein is not yet known. Finally, SIRT6 has recently 
been shown to be involved in the regulation of telomomeric DNA during s phase where 
the putative enzymatic target is K9 on H3 (Michishita et al.; 2008). 
               
 
 
Fig. 17 Histone deactylase (HDAC) family (classes I–IV) and HDACs implicated as disease 
modifiers. 
 
Fig. 17 Kazantsev AG, Thompson LM. Nat Rev Drug Discov. 2008 Oct;7(10):854-
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5.2 HDAC inhibitors and clinical use 
The HAT–HDAC system, owing to their involvement in turnover of histone and 
transcription machinery regulation, is one of the ultimate regulatory switches of gene 
expression. In addition to transcriptional regulation, HAT–HDAC system is also 
postulated to modulate other chromatin-associated processes like replication, site-
specific recombination and DNA repair, thereby playing a major role in modulating 
overall cellular fate. During normal conditions, protein concentration (availability) and 
enzymatic activity of HATs (like CBP and p300) and HDACs remain in a highly 
harmonized state of balance where adequate active molecules from either group are 
present to effectively regulate chromatin in a controlled manner (Fig. 18). Such 
equilibrium manifests neuronal homeostasis and is responsible for regulated gene 
expression leading to normal neurophysiological outputs like long-term potentiation, 
learning and memory. The maintenance of precise balance between HATs and HDACs 
as a prerequisite of neuronal survival in normal conditions. The loss of acetylation 
homeostasis alters significantly during neurodegenerative circumstances when histone 
acetylation level in neuron decreases globally, reflecting a malfunctioning acetylation 
apparatus (Rouaux  et al.; 2003) (Fig. 18). 
 Fig. 18 
Saha RN, Pahan K. (2006) Cell Death Differ. 13(4):539-50. 
Fig. 18 Neuronal acetylation homeostasis. (a) In neurons under normal conditions, the dose and activity of 
HATs and HDACs are poised in a fine balance where they counteract each other to ensure physiological 
homeostasis. (b) During neurodegeneration, critical loss of HAT protein level ensue a rebated HAT dose 
and activity. This reclines the acetylation balance towards excessive deacetylation of target moieties 
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Recent years have witnessed an explosion in the development of new HDAC inhibitors 
(Carey and La Thangue; 2006). HDAC inhibitors can be classified into four main 
chemical families, the shortchain fatty acids (e.g. sodium butyrate, phenylbutyrate, and 
valproic acid), the hyroxamic acids (e.g. trichostatin A and suberoylanilide hydroxamic 
acid (SAHA)), the epoxyketones (e.g. trapoxin), and the benzamides. Of these, the most 
widely studied are sodium butyrate, phenylbutyrate, trichostatin A, and SAHA. The 
butyrates are known to cross the blood–brain barrier (Carey and La Thangue; 2006; 
Minucci et al.; 2006). The initial interest in these inhibitors came from studies linking 
HDACs to a wide variety of human cancers. HDAC inhibitors arrest growth, induce 
differentiation and, in somecases, apoptosis and have potent anitcancer activities, with 
remarkable tumor specificity (Carey and La Thangue; 2006; Minucci et al.; 2006). For 
this reason, inhibitors of class 1 and 2 HDACs are in phase I/II clinical trials for cancer 
therapy and potentially cancer prevention. In the nervous system, the anticonvulsant and 
mood-stabilizing drug valproic acid was identified as an inhibitor of HDAC1, thereby 
linking its antiepileptic effects to changes in histone acetylation. More recent work has 
revealed that inhibitors of class 1 and 2 HDACs represent novel therapeutic approaches 
to treat neurodegenerative disorders, depression and anxiety, and the cognitive deficits 
that accompanymany neurodevelopmental disorders. 
 
Recent findings suggest that HDAC inhibitors can ameliorate deficits in synaptic 
plasticity, cognition, and stress-related behaviors in a wide range of neurologic and 
psychiatric disorders including Huntington’s disease, Parkinson’s disease, anxiety and 
mood disorders, Rubinstein- Taybi syndrome, and Rett syndrome. These agents may 
prove useful in the clinic for the treatment of the cognitive impairments that are central 
elements of many neurodevelopmental, neurological, and psychiatric disorders. 
In particular the develope of novel treatment strategies for neuroprotection, rescue, and 
repair in order to ameliorate the deleterious consequences of stroke. Global ischemia can 
arise as a consequence of cerebrovascular accidents, cardiac arrest, cardiac surgery, 
profuse bleeding, near-drowning, and carbon monoxide poisoning. Brief ischemic 
insults cause selective, delayed death of hippocampal CA1 neurons, and severe cognitive 
deficits. The substantial delay between insult and cell death is consistent with a role for 
transcriptional changes. The transcriptional repressor RE1 silencing transcription factor 
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(REST, also called NRSF) is widely expressed during embryogenesis and plays a crucial 
role in terminal neuronal differentiation (Ballas and Mandel, 2005; Roopra et al.; 2001). 
In neural progenitors and non-neural cells, REST actively represses a large array of 
neural-specific genes important to synaptic plasticity including synaptic vesicle proteins, 
structural proteins, voltage-gated channels, and ligand-gated receptors, allowing non-
neuronal transcripts to be expressed (Ballas and Mandel, 2005; Roopra et al.; 2001). As 
neurons differentiate, REST orchestrates a set of epigenetic modifications that 
distinguish neuronal from non-neuronal cells. In global ischemia, selectively vulnerable 
hippocampal neurons exhibit aberrant accumulation of REST/NRSF in the nucleus and 
REST-dependent silencing of target genes essential for neuronal function (Calderone et 
al.; 2003). A fundamental mechanism by which REST silences target genes is by 
recruitment of MeCP2 and corepressor complexes that promote histone H3 lysine 9 
(H3K9) deacetylation and methylation. Recent findings that REST recruits CoREST, 
G9a, and MeCP2 to promoters of target genes and promotes epigenetic remodeling of 
target genes in selectively vulnerable hippocampal neurons implicates REST-dependent 
epigenetic remodeling in the pathogenesis of global ischemia (Formisano et al.; 2007). 
Dysregulation of REST and its target genes is implicated not only in global ischemia but 
also in the pathogenesis of Down’s syndrome, AD Huntington’s disease, epilepsy, and 
X-linked mental retardation (Ballas and Mandel, 2005; Roopra et al.; 2001). Two recent 
studies demonstrate a role for HDAC inhibitors in amelioration of neuronal death and 
cognitive deficits in postischemic neurons. A study of our laboratory, (Faraco et al., 
2006) reports that the potent HDAC inhibitor SAHA administered intraperitoneally to 
mice at zero and six hours after induction of ischemic stroke by middle cerebral artery 
occlusion (MCAO) prevented H3 deacetylation, promoted expression of neuroprotective 
proteins Bcl-2 and Hsp70, and reduced infarct volume, indicating a neuroprotective 
action for SAHA (Faraco et al., 2006). In a second study, Moskowitz and colleagues 
observed aberrant DNA methylation in the brains of wild-type mice subjected to mild 
ischemic brain injury by the MCAO model; administration of the demethylating agent 5-
aza-20-deoxycytidine and the HDAC inhibitor trichostatin A conferred stroke protection 
in wild-type mice subjected to mild, but not severe ischemic damage (Endres  et al.; 
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2000). These findings underscore the therapeutic potential of HDAC inhibitors for 
therapeutic intervention in the neurodegeneration associated with stroke. 
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6. AIM OF THE STUDY 
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Ischemic tolerance is an evolutionary conserved cellular defense program in which 
exposure to a subtoxic preconditioning stimulus results in resistance to a subsequent 
lethal ischemic insult (Gidday, 2006; Steiger & Hanggi, 2007; Stenzel-Poore et al., 
2007; O’Duffy et al., 2007; Obrenovitch, 2008; Dirnagl et al., 2009). The key element in 
this process is the preconditioning stimulus and its ability to regulate neuronal activity, 
involving a number of transductional and traslational pathways that generate an array of 
mechanisms in which specific transducers lead to neuroprotection by modifying the gene 
expression of vulnerable cells. The endogenous molecular mechanisms of increased 
neuronal resistance induced by preconditioning offer attractive targets for the 
development of therapeutic strategies, but these processes are still not clearly 
understood.  
A number of possible molecular mediators of ischemic tolerance that determine 
either inhibition of programmed cell death or augmentation of programmed cell survival 
processes have been proposed. Particular attention among transducers has been devoted 
to ionotropic (iGlu) and metabotrobic glutamate (mGlu) receptors, which have been 
repeatedly demonstrated to be involved in the induction of tolerance to ischemia and 
excitotoxic insults. Recent studies have demonstrated that the mGlu 1/5 receptor agonist 
DHPG can be used as a preconditioning stimulus, being able to protect CA1 pyramidal 
cells in rat hippocampal slices from the deleterious effects of 30 min oxygen and glucose 
deprivation (OGD) (Blaabjerg et al., 2003; Werner et al., 2007). Moreover, low doses of 
NMDA in hippocampal neurons lead to neuroprotection activating diverse and multiple 
pathways (Grabb and Choi, 1999; Soriano et al., 2006).  
The aim of this study was to investigate whether modifications of glutamate 
receptors may underlie the tolerant responses to excitotoxicity induced by 
preconditioning.  
We know that modifications of MAGUK protein function in the glutamatergic 
synapse have been recently described in several neurological disorders such as 
Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Ischemia, 
Schizophrenia and neuropathic pain. In particular, modifications of MAGUK proteins 
interactions with NMDA receptors regulatory subunits are a common event in several 
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neurodegenerative disorders (Gardoni et al., 2006; Aarts et al., 2002) but are also 
involved in the induction of ischemic tolerance (Du et al., 2009). 
Moreover, the ability of preconditioning stimuli to regulate neuronal activity involves 
several translational pathways and generates an abounding system in which specific 
transducers lead to neuroprotection by modification of gene expression both in a rapid 
and delayed fashion (Dirnagl et al., 2003; Gidday, 2006) and shown to produce 
neuroprotection through various mechanisms, including moderate increases in the 
concentrations of intracellular calcium, the rapid release of brain-derived neurotrophic 
factor (BDNF), the formation of NO, the activation of the Ras/ extracellular signal-
regulated kinase (Erk) and phosphatidylinositol 3 (PI3)-kinase/Akt pathways, and the 
increased activity of the transcription factor NFκB (Gidday et al., 1999; Shamloo et al., 
1999; Gonzalez-Zulueta et al., 2000; Bickler and Fahlman, 2004). The induction of 
ischemic tolerance is accompanied by substantial change in gene expression, suggesting 
that preconditioning stimulates a fundamental genomic reprogramming of cells that 
confers cytoprotection and survival. 
To this aim, we further characterized a DHPG preconditioning paradigm recently 
described in a previous report (Werner et al., 2007) and developed a new 
pharmacological preconditioning protocol using subtoxic concentrations of NMDA. In 
the present study, we examined the role of group I mGlu receptors and NMDA receptors 
in both the induction and the expression of ischemic tolerance. We used organotypic 
hippocampal slices exposed to either pharmacological preconditioning paradigms. In 
particular, we examined whether activation of mGlu1 or NMDA receptors was 
necessary to initiate the process leading to ischemic tolerance. To this aim, we exposed 
organotypic hippocampal slices to our preconditioning protocols and 24 h later to 30 min 
OGD, which promotes selective CA1 pyramidal cell death. In particular, we have 
examined two different aspects in the induction of ischemic tolerance: the modulation in 
the Post Synaptic Density and the changes in gene expression. For the first point, we 
investigated whether MAGUK proteins and glutamate receptor responses could be 
modified in rat organotypic hippocampal slice models of pharmacological 
preconditioning. In particular we have looked at glutamate receptors subunits (NR2A or 
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NR2B for NMDA receptors and GluR1 for AMPA receptors) and at MAGUK proteins, 
in particular PSD95.  
For the second point, we choose to investigate the contribution of two classes of 
enzymes involved in gene modulation and early studied in our laboratory: PARP and 
HDACs. We know that both NMDA (Eliasson et al., 1997; Lo et al., 1998; Mandir et al., 
2000) and DHPG (Meli et al. 2005) can stimulate the activity of PARP-1, and that the 
dynamic chromatin remodeling events in hippocampal nerurons are associated with 
NMDA receptor-mediated activation and histone modulation (Tian et al., 2009).  
In particular, experimental evidence of our laboratory strongly suggest that PARP 
inhibitors may reduce brain damage after stroke (Meli et al., 2003) and that 
pharmacological inhibition of histone deacetylases specifically alters gene expression 
and reduces ischemic injury in the mouse brain (Faraco et al., 2006).  
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7. MATERIALS AND METHODS 
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7.1 Materials 
 
DHPG and staurosporine were purchased from Ascent Scientific (Weston-Super-
Mare, UK). Glutamate, NMDA, N-methyl-N-nitro-N-nitrosoguanidine (MNNG) and 
propidium iodide (PI) were purchased from Sigma (St Louis, MO, USA). Z-VAD-FMK 
(carbonbenzoxy-valyl-alanyl-aspartyl-[O-methyl]-fuoromethylketone) was purchased 
from Promega (Madison, WI, USA). Thieno(2,3-c)isoquinolin-5-one (TIQ-A) was 
synthesized as described in Pellicciari et al. (2003), whereas N-(6-oxo-5,6-dihydro-
phenanthridin-2-yl)-(N,N-dymethilamino)acetamide hydrochloride (PJ-34) was 
purchased from Alexis Biochemicals (Vinci, FI, Italy). Tissue culture reagents were 
obtained from Gibco-BRL (San Giuliano Milanese, MI, Italy) and Sigma (St Louis, MO, 
USA). 
 
 
7.2 Preparation of rat organotypic hippocampal slice cultures 
 
Organotypic hippocampal slice cultures were prepared as previously reported 
(Pellegrini-Giampietro et al., 1999a,b). Briefly, hippocampi were removed from the 
brains of 8–10 days old Wistar rats (Harlan, MI, Italy), and transverse slices (420 µm) 
were prepared using a McIlwain tissue chopper in a sterile environment. Slices were first 
placed in Hanks’ balanced salt solution (supplemented with 5 mg/ml glucose and 3.75 
mg/ml amphotericin B) and then transferred onto 30 mm diameter semiporous 
membranes inserts (Millicell-CM; Millipore, Italy), which were placed in sixwell tissue 
culture plates containing 1.2 ml medium per well. The slices culture medium consisted 
of 50% Eagle’s minimal essential medium, 25% heat-inactivated horse serum, 25% 
Hanks’ balanced salt solution, 5 mg/ml glucose, 2 mM L-glutamine, and 3.75 mg/ml 
amphotericin B. Slices were maintained at 37 °C in an incubator in atmosphere of 
humidified air and 5% CO2 and culture medium was changed twice a week. Slices were 
kept in culture for 12–14 days and before experiments all slices were screened for 
viability by incubating them for 30 min with PI (5 mg/ml); slices displaying signs of 
neurodegeneration were discarded from the study. 
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7.3 Oxygen and glucose deprivation in rat organotypic hippocampal 
slices 
 
Cultures were exposed to OGD as previously reported in detail (Pellegrini-
Giampietro et al., 1999a,b). Briefly, the slices were subjected to OGD by exposing them 
to a serum- and glucose-free medium saturated with 95% N2 and 5% CO2. Following 30 
min of incubation at 37 °C in an airtight anoxic chamber equipped with an oxygen gas 
controller (BioSpherix, New York, USA), the cultures were transferred to oxygenated 
serum-free medium (75% Eagle’s minimal essential medium; 25% Hank’s balanced salt 
solution; 2 mM L-glutamine; and 3.75 mg/ml amphotericin B) containing 5 mg/ml 
glucose and returned to the incubator under normoxic conditions until neuronal injury 
was evaluated 24 h later. 
 
 
7.4 OGD and exposure to glutamate receptor agonists  in rat 
organotypic hippocampal slices 
 
Cultures were exposed to OGD as previously reported in detail (Pellegrini-
Giampietro et al., 1999a; Pellegrini-Giampietro et al., 1999b). Briefly, the slices were 
subjected to OGD by exposing them to a serum- and glucose-free medium saturated with 
95% N2 and 5% CO2. Following 30 min of incubation at 37°C in an airtight anoxic 
chamber equipped with an oxygen gas controller (BioSpherix, New York, USA), the 
cultures were transferred to oxygenated serum-free medium (75% Eagle’s minimal 
essential medium; 25% Hank’s balanced salt solution; 2 mM L-glutamine; and 3.75 
µg/ml amphotericin B) containing 5 mg/ml glucose and returned to the incubator under 
normoxic conditions until neuronal injury was evaluated 24 h later.  
Exposure to the ionotropic glutamate receptor agonist NMDA (0.1-100 µM for 
15, 30 or 60 min) or to the group I metabotropic glutamate receptor (mGlu) agonist 
DHPG (0.1-300 µM for 30 min) was carried out in the incubator using serum-free 
medium as previously described (Pellegrini-Giampietro et al., 1999a). Hippocampal 
slices were then cultured for an additional 24 h in a fresh serum-free medium and then 
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evaluated for CA1 pyramidal cell injury. In order to achieve a maximal degree of 
neuronal injury, hippocampal slices were exposed for 24 h to 10 mM glutamate in the 
incubator using serum-free medium.  
 
 
7.5 Assessment of CA1 pyramidal cell injury 
 
Cell injury was assessed using the fluorescent dye PI (5 µg/ml), a highly polar 
compound which enters the cell only if the membrane is damaged and becomes 
fluorescent upon binding to DNA. PI was added to the medium at the end of the 24 h 
recovery period following OGD or exposure to NMDA or DHPG. Thirty minutes later, 
fluorescence was viewed using an inverted fluorescence microscope (Olympus IX-50; 
Solent Scientific, Segensworth, UK) equipped with a xenon-arc lamp, a low-power 
objective (4X) and a rhodamine filter. Images were digitized using a video image 
obtained by a CCD camera (Diagnostic Instruments Inc., Sterling Heights, MI, USA) 
controlled by software (InCyt Im1TM; Intracellular Imaging Inc., Cincinnati, OH, USA) 
and subsequently analyzed using the Image-Pro Plus morphometric analysis software 
(Media Cybernetics, Silver Spring, MD, USA). In order to quantify cell death, the CA1 
hippocampal subfield was identified and encompassed in a frame using the drawing 
function in the image software (ImageJ; NIH, Bethesda, USA) and the optical density of 
PI fluorescence was detected. There was a linear correlation between CA1 PI 
fluorescence and the number of injured CA1 pyramidal cells as detected by 
morphological criteria (Pellegrini-Giampietro et al., 1999a). 
 
 
7.6 Electrophysiological recordings in organotypic hippocampal slices 
 
NMDA and DHPG preconditioning was performed as described in paragraph 7.4. 
Whole-cell voltage-clamp recordings were performed and AMPA-stimulated inward 
currents were recorded in CA1 pyramidal cells from organotypic hippocampal slices 
preconditioned 24h before recordings. To this aim, a small rectangle of the membrane 
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surrounding an attached culture slice was excised with a scalpel blade, removed from the 
culture disch and placed into a recording bath submerged in 5%CO2/95%0O2 
oxygenated aCSF containing (in mM): NaCl 130, KCl 3.5, Na2H2PO4 3, NaHCO3, 
glucose, MgCl2 1.5 and CaCl2 1.5 at pH 7.4.  
Recording microelectrodes were prepared from borosilicate glass (WPI Inc; 
Sarasota, FL) by a Narishige Instruments micropipette puller (Tujunga, CA) (resistance 
ranging from 4 to 6 M_) and filled with solution of the following composition (in 
micromolar concentrations): K-gluconate 142.5, potassium methylsulfate 20, NaCl 8, 
Hepes 10, EGTA 0.1, MgATP 2, and GTP 0.2. The pH of the internal solution was 
adjusted to 7.2 with KOH and the osmolarity was adjusted to 300 mOsm with H2O and 
sucrose. After establishing a GIGA seal a whole-cell configuration was achieved by 
rupturing the membrane. Recordings were done using a Multiclamp preamplifier (Axon 
Instruments; Foster City, CA) and filtered at 5 kHz. Both the frequency and peak 
amplitude of detected events were analyzed (Fig. 7D). 
The AMPA receptor blocker NBQX (10 µM) was added at the end of each 
experiment to verify that the spontaneous AMPA-stimulated inward currents were 
AMPA receptor-mediated. 
Application of 1 µM TTX was used during the experimental recordings in a 
second set of experiments to verifye a possible presynaptic mechanism mediated by our 
preconditioning paradigms (Fig. 7E).  
 
 
7.7  TIF (triton insoluble fraction) preparation 
 
Cultured slices were homogenized in 0.32 M cold sucrose containing 1mM HEPES, 1 
mM MgCl2, 1 mM NaHCO3, and 0.1 mM PMSF, pH 7.4 in the presence of a complete 
sets of proteases inhibitors (CompleteTM) and phosphatase inhibitors. The homogenized 
tissues were centrifuged at 1,000 g for 10 min. The resulting supernatant were 
centrifuged at 13,000 g for 15 min to obtain a fraction of mitochondria and 
synaptosomes. The pellet were resuspended in hypotonic buffer (in the presence of 
protease inhibitors) in a glass–glass potter and centrifuged at 140,000 g for 1 h. The 
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pellet was resuspended in 1 ml of buffer containing 150 mM KCl and 1% Triton X-100 
and centrifuged at 140,000 g for 1 hr 4°C. The final pellet was homogenized by 10 
strokes in a glass–glass potter in 20 mM HEPES. An equal volume of glycerol were 
added and stored at -80°C. This fraction is enriched in proteins composing the 
postsynaptic compartment and is referred to as the “Triton-Insoluble Fraction” (TIF). 
 
 
7.8 Western blot analysis  
 
Cultured slices were washed with cold 0.01 M phosphate-buffered saline, pH 7.4 
and 4 slices/sample were gently transferred and dissolved in a tube containing 1% SDS. 
Total protein levels were quantified using the Pierce (Rockford, IL, USA) BCA 
(bicinchoninic acid) Protein Assay. Lysates (20 µg/lane of protein) were resolved by 
electrophoresis on a 4-20% SDS-polyacrylamide gel (Bio-Rad Laboratories, Hercules, 
CA, USA) and transferred onto nitrocellulose membranes. Blots were blocked for 1 h at 
room temperature in 20 mM Tris-buffered saline, pH 7.6 - 0.1% Tween 20 (TBS-T) 
containing 5% non-fat dry milk, and then incubated overnight at 4°C with monoclonal 
anti-PAR (10H) antibody (Alexis Biochemicals, Vinci, FI, Italy) or with polyclonal 
rabbit anti-PARP-1, anti- phospho ERK,  antibody (Cell Signaling Technology, Beverly, 
MA, USA) diluted both 1:1000 in TBS-T containing either 5% non-fat dry milk (anti-
PAR) or 5% bovine serum albumin (anti-PARP-1). Immunodetection was performed 
with secondary antibodies (1:2000 anti-mouse or anti-rabbit IgG from donkey, 
Amersham Biosciences, UK) conjugated to horseradish peroxidase in TBS-T containing 
5% non-fat dry milk. Membranes were washed with TBS-T (3 X 15 min) and then 
reactive bands were detected using chemiluminescence (ECLplus; Euroclone, Padova, 
Italy). Quantitative analysis was performed using the QuantityOne analysis software 
(Bio-Rad, Hercules, CA, USA). 
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7.9 Measurement of NAD+ and ATP contents in organotypic 
hippocampal slices 
 
NAD+ contents were quantified by means of an enzymatic cycling procedure as 
described by Shah et al. (1995), while ATP levels were measured using the ATPliteTM 
Luminescence ATP Detection Assay System (Perkin-Elmer, Waltham, MA, USA). 
Specifically, for NAD+ contents, cultured slices were washed with cold 0.01 M 
phosphate-buffered saline, pH 7.4 and 2 slices/sample were gently transferred and 
dissolved in 100 µl of HCLO4 1N, sonicated and neutralized with 100 µl di KOH 1N. 
200 µl bicine 100 ml/L (pH 8) were added and the samples were centrifuged at 14.000 g 
for 5 min. Then, 100 µl of homogenate were transferred onto white multiwell plates with 
100 µl of buffer containing bicine, 23 µl/ml ethanol, 0.17 mg/ml MTT, 0.57 mg/ml 
fenazine etosolfate and 10 µg di alcool dehidrogenase and luminescence was measured 
using a luminescence counter.  
 
 
7.10 Caspase 3 activity dosage 
 
Caspase-3 and -7 activities were assessed using the Caspase-Glo® 3/7 Assay kit 
(Promega, Madison, WI, USA). Organotypic hippocampal slices were washed with cold 
0.01 M phosphate-buffered saline, pH 7.4 and 2 slices/sample were gently transferred 
into an Eppendorf tube containing 110 µl of Caspase-Glo® 3/7 reagent and maintained at 
22 °C for 1 h. Then, 100 µl of lysate were transferred onto black multiwell plates and 
luminescence was measured using a TopCount-NXTTM (Packard, Warrenville, Illinois, 
USA) microplate scintillation and luminescence counter.  
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7.11 PARP pure activity dosage 
 
PARP activity assay 3H-PAR was synthesized in vitro according to Banasik et al. 
(1992). Briefly, 0.05U of purified bovine PARP-1 was incubated at 37 1C in a final 
volume of 100mL 50mM Tris-HCl buffer (pH 7.4), containing 5mM MgCl2, 2mM DL-
dithiothreitol, 10 mg sonicated DNA, 0.5mgmL_1 bovine albumin, 10 µM NAD+ and 1 
µL 3H-NAD (35.5nmol). Afterm 60 min, PARP-1 activity was blocked with 30 µM 
PJ34, 10 mM nicotinamide or SAHA 10 µM. After  60 min incubation at 37 1C, the 
reaction was stopped by adding 1mL of trichloroacetic acid (TCA) 10% (w/v). Then, the 
mixture was centrifuged (15min at 12 000 g at 4 1C), and the pellet containing 3H-PAR 
was washed twice with water and resuspended in 0.1mM NaOH. Radioactivity was 
measured by scintillation counting (Tri-Carb 1900 TR; Packard, Meriden, CT, USA).  
 
 
7.11 Statistical analysis 
 
Statistical significance of differences between PI or DCF fluorescence intensities 
and Western blot optical densities was evaluated by performing analysis of variance 
(ANOVA) followed by the Tukey’s w test for multiple comparisons. Differences were 
considered significant for P <0.05. 
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8. RESULTS 
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PART I 
 
8.1 Ischemic and pharmacological preconditioning in organotypic 
hippocampal slices 
 
As previously reported (Pellegrini-Giampietro et al., 1999a; 1999b), maximal damage 
was achieved in this system by exposing organotypic hippocampal slices to 10 mM 
glutamate for 24 h (Fig. 1A). Exposure to OGD for periods ranging from 10 to 30 min 
led 24 h later to selective and time-dependent increases in the levels of PI fluorescence 
in the CA1 region (Fig. 19).  
 
Fig. 19  Sublethal, mild and severe OGD in organotypic hippocampal slices 
 
CA1 injury was modest but significant when slices were exposed to 20 min OGD and 
increased to approximately 65% and 85% of the fluorescence intensity observed with 10 
mM glutamate when slices were exposed, respectively, to 25 and 30 min OGD. 
  We have previously shown that exposure of organotypic hippocampal slices to 
iGlu and mGlu receptor agonists such as NMDA, α-amino-3-hydroxy-5-methyl-4-
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isoxazole (AMPA) or DHPG at relatively large concentrations or for prolonged periods 
of time results in extensive damage in all pyramidal cell layers (Werner et al., 2007; 
Scartabelli et al., 2008). Because it has been shown that tolerated doses of glutamate 
receptor agonists may be neuroprotective, we seeked to develop pharmacological models 
of preconditoning by first establishing which was the toxic threshold in our system for 
for NMDA, that has been used as a preconditioning stimulus in various in vitro culture 
models (Grabb & Choi, 1999; Raval et al., 2003; Soriano et al., 2006). NMDA induced 
significant increases in CA1 PI fluorescence 24 h later starting at 10 µM when added to 
the incubation medium for 60 min, at 30 µM when incubated for 30 min, and at 30-100 
µM when incubated for 15 min (Fig. 20). 
 
Fig. 20 NMDA toxicity in organotypic hippocampal slices 
 
 When the highest concentration of DHPG that was tolerated without producing a 
toxic response (i.e., 10 µM) was added to the incubation medium for 30 min, the CA1 
injury induced 24 h later by a 30 min exposure to OGD was reduced by approximately 
50%. Previous exposure to a slightly toxic concentration of DHPG (100 µM for 30 min) 
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did not induce tolerance but rather exacerbated the subsequent neuronal death induced 
by OGD (Fig. 21 A and 21 B).  
 
 
 
Fig. 21A & 21B. Slices were exposed to 10 µM DHPG for 30 min and then, 24 h later, to 30 min OGD.  Quantitative 
data are expressed as percentage of Glutamate-induced CA1 totoxicity and show that DHPG preconditioning reduced 
OGD injury. Bars represent the mean ± SEM of at least 4 experiments. **P<0.01 and *P<0.05 vs. AMPA 
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Similarly, we tested the neuroprotective potential of various concentrations of NMDA 
that were below (1 and 3 µM for 30 and 60 min, 10 µM for 30 min) or slightly above (10 
µM for 60 min) the toxic threshold, and observed that pre-exposure of hippocampal 
slices to 1 and 3 µM, but not to 10 µM NMDA, was able to reduce the subsequent CA1 
injury induced by 30 min OGD (Fig. 22).  
 
Fig. 22. Slices were exposed to 1, 3 or 10 µM NMDA for 30 or 60 min and then, 24 h later, to 30 min 
OGD.  Quantitative data are expressed as percentage of glutamate-induced CA1 toxicity and show that 
preconditioning at 1-3 µM NMDA, but not at higher concentrations, significantly reduced OGD injury. 
Red arrow depicts the paradigm that was selected for all subsequent experiments. Bars represent the mean 
± SEM of at least 4 experiments. **P<0.01 and *P<0.05 vs. glutamate. 
 
 
Pre-exposure to 3 µM NMDA for 60 min produced the highest degree of tolerance (by 
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the neuronal damage induced in organotypic hippocampal slices by a toxic exposure to 
10 µM NMDA for 24 h (not shown). 
In order to evaluate the mechanisms leading to tolerance towards the OGD insult, 
we investigated the effects of pharmacological preconditioning on the subsequent 
neurotoxicity induced by ionotropic glutamate receptor agonists AMPA. Exposure of 
slices to AMPA (10 µM) for 24 h produced a pattern of neurotoxicity, as observed 24 h 
later, that was slightly more intense and less selective for CA1 than that induced by 30 
min OGD (Fig. 23A). 
 
 
 
 
 
 
Fig. 23 A 
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When we tested whether a 24-h preexposure to preconditioning stimuli could 
affect AMPA toxicity, we observed that  the pharmacological preconditioning paradigms 
reduced the neurotoxicity caused by 10 µM AMPA (Fig. 23B). 
 
 
Fig. 23A & 23B. Slices were exposed to 3 µM NMDA for 60 min or to 10 µM DHPG for 30 min and 
then, 24 h later, to 10 µM AMPA for the subsequent 24 h.  Quantitative data are expressed as percentage 
of AMPA-induced CA1 excitotoxicity and show that NMDA and DHPG preconditioning reduced AMPA 
injury. Bars represent the mean ± SEM of at least 4 experiments. **P<0.01 and *P<0.05 vs. AMPA. 
 
 
 
 
 
 
 
 
 
 
Fig. 23B 
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8.2 AMPA currents following NMDA pharmacological 
preconditioning in organotypic hippocampal slices 
 
To investigate the possible mechanisms by wich pyramidal neurons are able to 
develop tolerance to NMDA or AMPA excitotoxic insults, whole-cell voltage-clamp 
recordings were performed on control or preconditioned CA1 pyramidal neurons in rat 
organotypic hippocampal slices. To this aim, the slices are exposed to preconditionant 
doses of NMDA or DHPG and, 24h later, AMPA-stimulated inward currents recorded in 
CA1 pyramidal cells from organotypic hippocampal slices were measured using the 
patch clamp technich in whole cell configuration (Fig. 24A). Our results show that, 
when the slices are exposed to both our preconditioning stimuli 24h before the 
recordings, the AMPA induced-currents are significantly reduced (Fig. 24A).  
 
 
 
Fig. 24A. AMPA-stimulated inward currents recorded in CA1 pyramidal cells from organotypic 
hippocampal slices. Experimental protocol: NMDA and DHPG preconditioning was performed as 
described in panel 2. Whole-cell voltage-clamp recordings were performed after 24 h from 
preconditioning. Example of a typical experiment showing AMPA-induced (open bar) inward currents 
under control conditions. The figure also shows the inhibitory action of NBQX (10 µM; filled bar) on 
sEPSCs.  
Fig. 24A 
 77 
 
Fig. 24B describe how in control slices (solid circles), AMPA induced a clear 
increase of the holding current (Ihold) that was significantly reduced in slices 
preconditioned with DHPG (open circles) or with NMDA (open square).  Bar graph 
showing the AMPA-induced inward current peak value in control and in preconditioned 
slices.  
 
 
 
Fig. 24B. AMPA-stimulated inward currents recorded in CA1 pyramidal cells from organotypic 
hippocampal slices. In control slices (solid circles), AMPA induced a clear increase of the holding current 
(Ihold) that was significantly reduced in slices preconditioned with DHPG (open circles) or with NMDA 
(open square). Bar graph showing the AMPA-induced inward current peak value in control and in 
preconditioned slices. The number of cell tested is in parenthesis; data are shown as mean ± SEM, *P  
0.05, **P  0.01 using  2 way ANOVA followed by Bonferroni post-tests. 
 
 
Fig. 24B 
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Fig. 24C shows an example of a typical experiment showing AMPA-induced 
sEPSCs in control or 24 h after NMDA/DHPG preconditioning. Curve represent the 
cumulative probability plots demonstrating the effect of NMDA/DHPG preconditioning 
on sEPSC inter-event interval and amplitude. (Kolmogorov- Smirnov (K ± S) statistic 
P50.01).  
 
 
 
 
Fig. 24C. The traces show an example of a typical experiment showing AMPA-induced sEPSCs in 
control or 24 h after NMDA/DHPG preconditioning. Curve represent the cumulative probability plots 
demonstrating the effect of NMDA/DHPG preconditioning on sEPSC inter-event interval and amplitude. 
(Kolmogorov- Smirnov (K ± S) statistic P50.01).  
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In Fig. 24D, bar graphs show the value of the AMPA-induced effect on sEPSC 
frequency and amplitude in control and in NMDA or DHPG preconditioned slices. Our 
results show that 24 h following NMDA/DHPG preconditioning, the increase on 
AMPA-induced frequency was significantly reduced. On the other hand, the AMPA-
induced amplitude was significantly reduced only after NMDA but not DHPG 
preconditioning. 
 
 
 
 
Fig. 24D. Bar graphs show the value of the AMPA-induced effect on sEPSC frequency and amplitude in 
control and in NMDA or DHPG preconditioned slices. Our results show that 24 h following 
NMDA/DHPG preconditioning, the increase on AMPA-induced frequency was significantly reduced. On 
the other hand, the AMPA-induced amplitude was significantly reduced only after NMDA but not DHPG 
preconditioning, Bars represent the mean of at least 4 experiments. *P<0.05 vs. CTRL. 
 
 
 
 
 
 
 
Fig. 24D 
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Fig 24E, To investigate a possible involvement of presynaptic terminal and a 
different mechanisms of NMDA or DHPG induced-ischemic tolerance, AMPA-
stimulated inward currents were recorded in CA1 pyramidal cells from organotypic 
hippocampal slices in the presence of tetrodotoxin (TTX).  Application of  1 µM TTX 
does not modify AMPA-induced inward currents in control (solid circles), in NMDA 
(open square) and in DHPG (open circle) preconditioned slices, suggesting a possible 
presynaptic mechanism in the induction of tolerance in both of our preconditioning 
paradigms. Bar graph showing the AMPA-induced inward current peak value in control 
and in preconditioned slices. 
 
Fig. 24E. AMPA-stimulated inward currents recorded in CA1 pyramidal cells from organotypic 
hippocampal slices in the presence of tetrodotoxin (TTX). Application of  1 µM TTX does not modify 
AMPA-induced inward currents in control (solid circles), in NMDA (open square) and in DHPG (open 
circle) preconditioned slices, suggesting a possible presynaptic mechanism in the induction of tolerance in 
both of our preconditioning paradigms. The numbers of cell tested are in parenthesis. Bar graph showing 
the AMPA-induced inward current peak value in control and in preconditioned slices. 
Fig. 24E 
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8.3 Modulation of glutamate receptor subunits following 
pharmacological preconditioning in organotypic hippocampal slices 
 
To better comprehend the mechanisms leading to tolerance towards the AMPA insult, 
we investigated the effects of pharmacological preconditioning on the post synaptic 
density. In particular, we choose the phosphorylation of: NMDA subunits NR2A and 
NR2B, AMPA subunit GluR1, PSD95 or CAMKII. To this aim, hippocampal slices 
were treated with NMDA or DHPG preconditioning protocols and homogenate or TIF 
extract was prepared immediately or after 24 h the preconditioning treatment and 
processed by western blot analysis. Our results show that following 24 h after NMDA 
preconditioning, the expression of GluR1 was significantly reduced, while NR2A, 
NR2B, αCaMKII and PSD-95 immunostaining in the TIF were not affected (Fig. 25A). 
 
 
 
Fig. 25A. Expression of GluR1, NR2A and  NR2B subunits, αCaMKII and PSD-95, in organotypic slices 
lysed immediately or 24 h after the preconditioning stimuli. Western blot analysis were performed in the 
homogenate (Homo) and postsynaptic TIF (triton insoluble fraction). 24 h after NMDA preconditioning, 
the expression of GluR1 was significantly reduced, while NR2A, NR2B, αCaMKII and PSD-95 
immunostaining in the TIF were not affected. Data are expressed as percentage of control. Bars represent 
the mean ± SEM of at least 3 experiments. **P<0.01 and *P<0.05 vs. CRL 
Fig. 25A 
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On the contrary, following DHPG preconditioning, we have observed no changes in the 
expression of GluR1, NR2A, NR2B, αCaMKII and PSD-95 immunostaining in the TIF 
or homogenate extract (Fig. 25B). 
 
 
 
 
 
Fig. 25B. Expression of GluR1, NR2A and  NR2B subunits, αCaMKII and PSD-95, organotypic slices 
lysed immediately or 24 h after the preconditioning stimuli. Western blot analysis were performed in the 
homogenate (Homo) and postsynaptic TIF (triton insoluble fraction). Our results show that following 
DHPG preconditioning, the expression of GluR1, NR2A, NR2B, αCaMKII and PSD-95 immunostaining 
in the TIF were not affected. Data are expressed as percentage of control. Bars represent the mean ± SEM 
of at least 3 experiments. 
 
 
 
 
 
 
 
 
Fig. 25B 
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8.4 NMDA but not DHPG pharmacological preconditioning induces 
GluR1 internalization in organotypic hippocampal slices 
 
To verify a possible AMPA interalization induced by our preconditioning 
paradigms, we used the cross-linker Bis(Sulfosuccinimidyl) suberate (BS3) in 
organotypic slices preconditioned 24h before the treatment and then we evaluated the 
expression level of GluR1. Western blotting analysis reveals that NMDA but not DHPG 
treatment induces GluR1 internalization, suggesting a different mechanism of induced 
neuroprotection. (Fig. 26).  
 
 
 
 
Fig. 26. Organotypic slices were preconditioned with both NMDA and DHPG and treated, 24 h later, 
with the cross-linker bis(sulfosuccinimidyl) suberate (BS3). The expression levels of GluR1 were then 
evaluated by western blotting analysis, revealing that NMDA, but not DHPG preconditioning, increased 
the internalization of GluR1. Data are expressed as percentage of BS3-treated control. Bars represent the 
mean ± SEM of at least 4 experiments. **P<0.01 and *P<0.05 vs. BS3-treated control 
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Working Hypothesis: Fig. 27 
 
 
 
 
Fig. 27  Under physiological conditions (CTRL), the presynaptic terminals release glutamate that 
act on AMPA postsynaptic receptors.  We hypothesize that our preconditioning paradigms (DHPG 
PC and NMDA PC) modulate the level of glutamate release and/or the number of postsynaptic 
AMPA receptors on to the membrane. 
 
 
 
 
 
 
Fig. 27 
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PART II 
 
8.5 Effects of PARP inhibitors on the induction of ischemic or 
pharmacological preconditioning 
 
To determine the role of PARP-1 in the induction of pharmacological 
preconditioning, we used TIQ-A, a PARP-1 inhibitor characterized in our laboratory 
(Chiarugi et al., 2003). Fig. 28 shows that TIQ-A completely prevented the induction of 
tolerance to OGD induced by both DHPG and NMDA in a dose-dependent manner 
when present in the incubation medium during exposure of slices to the preconditioning 
agents (15 min preincubation plus 30 min for DHPG or 60 min for NMDA) and the 
subsequent 24 h recovery period. Another PARP-1 inhibitor, namely PJ34 (Abdelkarim 
et al., 2001), also prevented the neuroprotective effects of NMDA preconditioning under 
the same experimental conditions (data not shown). Our data suggest a possible 
involvement of PARP in the induction of tolerance.  
 
 
Fig. 28. The tolerance induced by NMDA and DHPG was significantly reverted by TIQ-A (0.1 -100 µM) 
in a dose-dependent manner. Data were expressed as percentage of 30 min OGD-induced CA1 toxicity. 
Bars represent the mean ± SEM of at least 4 experiments. **P<0.01 and *P<0.05 vs. 30 min OGD. 
 
Fig. 28 
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8.6 Involvement of PARP on the induction of ischemic tolerance 
 
To directly evaluate the activation of PARP-1 under our experimental conditions, 
we examined the formation of its product, the PAR polymer, in organotypic 
hippocampal slices immediately after their exposure to preconditioning concentrations 
of NMDA and DHPG (Fig. 29).  
 
 
           Fig.  29  
 
Fig. 29.  Hippocampal slices were exposed to 10 µM TIQ-A, 3 µM NMDA or NMDA +TIQ-A for 60 
min, 10 µM DHPG or DHPG + TIQ-A for 30 min, or 100 µM MNNG for 5 min and then lysed and 
processed for Western blot with an anti-PAR antibody (Alexis). PARP activity, as detected by the 
formation of PAR, was increased after exposure to preconditioning concentrations of NMDA and DHPG. 
This increase was prevented when TIQ-A was added to the medium. Quantitative analysis of Western 
blots are expressed as percentage of control PARP activity. Bars represent the mean ± SEM of at least 4 
experiments. **P<0.01 and *P<0.05 vs. control 
 
Western blot analysis with an anti-PAR antibody revealed that both 
preconditioning protocols induced an increase in PAR formation that was significant but 
relatively modest as compared to that evoked by the alkylating agent MNNG, and was 
completely prevented by the presence of 10 µM TIQ-A in the incubation medium. 
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Interestingly, the important activation of PARP-1 induced by MNNG was associated 
with a dramatic decrease of cellular NAD+ and ATP levels that was evident up to 4 h 
after exposure to the alkylating agent, whereas NMDA and DHPG produced only slight, 
transient and non-significant reductions (Fig. 9B). At any rate, the reductions in NAD+ 
and ATP observed immediately after exposure to NMDA, DHPG and MNNG appeared 
to be PARP-1-dependent in that they were all prevented by the use of TIQ-A (Table 2). 
Table 1. NAD+/ATP consumption in preconditioned hippocampal slices is dependent on 
PARP-1 activity.   
    NAD+    ATP 
    Absorbance (nm) (%)  Counts per second (%) 
 
Basal    0.32 ± 0.08 (100)  106,434 ± 25,551 (100) 
10 µM TiQ-A 60 min  0.36 ± 0.12 (112)    95,903 ± 35,256 (90) 
3 µM NMDA 60 min  0.28 ± 0.07 (86)    80,611 ± 21,062 (75) 
NMDA + TiQ-A  0.30 ± 0.07 (93)  116,007 ± 31,790 (108) 
10 µM DHPG 30 min  0.24 ± 0.05 (74)    68,191 ± 15,791 (64) 
DHPG + TiQ-A 5 min 0.37 ± 0.21 (115)  104,486 ± 30,906 (98) 
100 µM MNNG  0.19 ± 0.04* (58)    41,808 ± 13,017* (39) 
MNNG + TiQ-A  0.26 ± 0.11 (80)  104,572 ± 50,000 (98) 
 
Tab. 2 Slices were exposed to drugs as indicated and then assayed to determine NAD+ or ATP cellular 
levels immediately after the treatment. TIQ-A was added to the incubation medium 15 min prior to and 
during the period of incubation with the other agents. Results are expressed as nm of absorbance for 
NAD+ and as counts per minute for ATP, as well as percentage of basal NAD+ or ATP levels in untreated 
slices. The modest nonsignficant decrease in NAD+ and ATP levels induced by preconditioning with 
NMDA and DHPG, as well as the robust decrease induced by MNNG, were all prevented by TIQ-A. 
Values represent the mean ± SEM of at least 3 experiments run in triplicate. *P<0.05 vs. basal (ANOVA + 
Tukey's w test). 
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8.7 Involvement of caspase-3 in the induction of ischemic tolerance 
 
Because caspase-3 activation has been shown to be essential for neuroprotection 
in preconditioning (McLaughlin et al., 2003; Garnier et al., 2003), we examined its role 
in our models by using the caspase inhibitor Z-VAD-FMK. Fig. 30A shows that 
neuroprotection induced by both DHPG and NMDA preconditioning was prevented 
when 100 µM Z-VAD-FMK was added to the incubation medium during exposure of 
slices to the preconditioning agents and the subsequent 24 h recovery period. We then 
examined the activity of caspase 3/7 in preconditioned slices and following incubation 
with 10 µM staurosporine for 24 h, a condition that is known to induce apoptotic cell 
death in this system (Meli et al., 2004).  
 
 
 
Fig. 30 A Caspase activity is required for the induction of DHPG and NMDA preconditioning in rat 
organotypic hippocampal slices. Schematic diagram showing that slices were incubated with the caspase 
inhibitor Z-VAD-FMK 15 min before preconditioning (PC), during PC, and during the subsequent 24 h 
recovery period. CA1 injury was assessed 24 h later by assessing the optical density of PI fluorescence 
(PI-OD) in this region. Quantitative analysis of CA1 PI fluorescence expressed as percentage of 30 min 
OGD-induced CA1 toxicity, showing that the tolerance induced by DHPG (B), NMDA were significantly 
reverted by 100 µM Z-VAD-FMK. Bars represent the mean ± SEM of at least 4 experiments. *P<0.05 vs. 
30 min OGD (ANOVA + Tukey's w test). 
 
Fig. 30A 
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Exposure of hippocampal slices to DHPG and NMDA preconditioning produced 
an increase in caspase-3/7 activity 1 h later that was significant but modest as compared 
to that induced by staurosporine and was completely prevented by the presence of 100 
µM Z-VAD-FMK in the incubation medium (Fig. 30B).  
 
Fig. 30 B Caspase 3/7 activation in preconditioned hippocampal slices. Slices were exposed to either the 
NMDA (3 µM for 60 min) or DHPG (10 µM for 30 min) preconditioning protocol and processed 1 h later. 
Z-VAD-FMK (100 µM) was added to the incubation medium 15 min before and during the 
preconditioning exposure. Caspase 3/7 activity, as detected by the Caspase-Glo®3/7 Assay kit, was 
increased in preconditioned slices, but to a lesser extent as compared to incubation with 10 µM 
staurosporine for 24 h. Data are expressed as percentage of control caspase 3/7 activity. Bars represent the 
mean ± SEM of at least 3 experiments. **P<0.01 and *P<0.05 vs. control (ANOVA + Tukey's w test). 
 
 
Sublethal caspase activation has been shown to result in PARP-1 cleavage that 
leads to ischemic tolerance (Garnier et al., 2003). Hence, we examined whether caspase-
3/7 activation could determine PARP-1 cleavage under our experimental conditions by 
using an antibody that detects endogenous levels of full length PARP-1 (116 kDa), as 
well as the large fragment (89 kDa) of PARP-1 resulting from caspase cleavage (Fig. 
10C). Western blot analysis revealed that PARP-1 was cleaved only when organotypic 
slices were exposed to 10 µM staurosporine for 24 h and not when they were collected 
and processed immediately (Fig. 30C) or 24 h (data not shown) after exposure to either 
of the three preconditioning paradigms used in this study. 
 
Fig. 30B 
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Fig. 30 C PARP-1 is not cleaved following pharmacological and ischemic preconditioning in rat 
organotypic hippocampal slices. Slices were exposed to either 3 µM NMDA for 60 min, 10 µM DHPG for 
30 min or 10 min OGD and then lysed and processed for Western blot with an antibody directed against 
both full length PARP-1 (116 kDa) and the large fragment (85 kDa) resulting from caspase cleavage. 
PARP-1 was not cleaved in our three preconditioning models as compared to incubation with 10 µM 
staurosporine for 24 h. The numbers on the right indicate the position of the molecular mass markers in 
kilodaltons (kDa). 
 
 
 
 
 
 
 
 
 
 
 
Fig. 30C 
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Working Hypothesis: Fig. 31 
 
 
 
 
 
 
 
 
 
 
 
Fig. 31 
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PART III 
 
8.8 Effects of HDACs inhibitors on OGD and on the induction of 
ischemic tolerance in organotypic hippocampal slices 
 
As previously reported (Faraco et al., 2006), pharmacological inhibition of histone 
deacetylases by SAHA reduces MCAO induced-ischemic injury in the mouse brain. We 
tested the effect of HDAC inhibitors on OGD in our model of organotypic hippocampal 
slices. Fig. 32 shows that exposing hippocampal slices to SAHA (10 µM) or sodium 
butirrate (100 µM) during 30 min OGD and during the subsequent 24 h recovery period, 
we observed a significant neuroprotection approximately 25% in CA1 region. On the 
contrary, culture slices esposed to 10 µM SAHA for 1 or 3 h, 24 h before 30 min OGD 
were not able to be preconditioned (10 µM SAHA is not able to induce tolerance). 
 
 
Fig. 32 The HDAC inhibitors SAHA and sodium butirrate was added to the incubation medium 15 min 
prior, during 30 min OGD and during the subsequent 24 h recovery period. Data are expressed as 
percentage of 30 min OGD-induced CA1 toxicity. Bars represent the mean ± SEM of at least 4 
experiments. **P<0.01 and *P<0.05 vs. 30 min OGD. 
Fig. 32 
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8.9 Involvement of HDACs on the induction of ischemic tolerance 
 
To determine the role of HDACs in the induction of pharmacological 
preconditioning, we used SAHA (1 and10 µM) and sodium butirrate (10 and 100 µM), 
two HDACs inhibitors. Fig. 33 shows that both inhibitors completely prevented the 
induction of tolerance to OGD induced by NMDA in a dose-dependent manner when 
present in the incubation medium during exposure of slices to the preconditioning agents 
(15 min preincubation plus 60 min for NMDA) and the subsequent 24 h recovery period.  
 
 
Fig. 33 The HDAC inhibitors SAHA and sodium butirrate was added to the incubation medium 15 min 
prior, during preconditioning and during the subsequent 24 h recovery period. Data are expressed as 
percentage of 30 min OGD-induced CA1 toxicity. The tolerance induced by NMDA was significantly 
reverted by SAHA and sodium butirrate when incubated in a dose dependent manner. Bars represent the 
mean ± SEM of at least 4 experiments. **P<0.01 and *P<0.05 vs. 30 min OGD. 
 
In order to establish which was the critical period for the beneficial involvement 
of HDACs in the development of tolerance to OGD, we added SAHA to the incubation 
medium only during the 60 min exposure to a preconditioning dose of NMDA (Fig. 
Fig. 33 
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34B, “Pre”) or during the subsequent 3, 6 or 24 h recovery period (Fig. 14B). Our results 
show that the development of tolerance to OGD could be abolished only when HDACs 
were inhibited during the exposure to the preconditioning stimulus and until 6h after 
treatment, not at early time points (Fig. 34 A and 34 B). 
 
 
 
Fig. 34 a & 34B.  Slices were exposed to 3 µM NMDA for 60 min then, 24 h later, to 30 min OGD.  
The HDAC inhibitor SAHA was added to the incubation medium 15 min prior, during 30 min OGD and 
during the subsequent 24 h recovery period. Data are expressed as percentage of 30 min OGD-induced 
CA1 toxicity. The tolerance induced by NMDA was significantly reverted by SAHA in a time-dependent 
manner. SAHA was not able by itself to induce tolerance when added to the incubation medium for 1 or 
3h, 24 h before 30 min OGD challenge. Bars represent the mean ± SEM of at least 4 experiments. 
**P<0.01 and *P<0.05 vs. 30 min OGD. 
Fig. 34B 
Fig. 34A 
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8.10 Interplay between PARP and HDACs activities on the induction of 
ischemic tolerance 
 
We have previously demonstrated the involvement of PARP in the induction of 
ischemic tolerance in the same preconditioning paradigm (PART II). To evaluate the 
activity of HDACs in our preconditioning model and the possible interplay with PARP, 
we carried out western blotting experiments using antibodies against the poly(ADP-
ribose) (PAR) polymer product and against the histone H3 acetylated in lysine (K) 18 
(Fig. 35).  
 
 
 
 
 
3h after the preconditioning stimulus we observed  a sligh increase in H3 (K18) 
acetylation as compared with the dramatic increase induced by the HDAC inhibitor 
SAHA (Fig. 36A).  
Fig. 35 
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Fig. 36A Hippocampal slices were exposed to 3 µM NMDA for 60 min and then left to recover for 3, 6, 
12 or 24 h. Slices were then lysed and processed for Western blot with an anti-acetyl H3 (K18) antibody 
(Cell Signaling). We observed a significant NMDA-induced increase in H3 acetylation 3 h after the 
preconditioning stimulus, that was prevented when TIQ-A was added to the incubation medium during 60 
min of NMDA treatment and during the subsequent 3 h, as compared with the dramatic increase induced 
by the HDAC inhibitor SAHA. Quantitative analysis of Western blots are expressed as percentage of 
control H3 acetylation. Bars represent the mean ± SEM of at least 4 experiments. **P<0.01 and *P<0.05 
vs. control.  
 
Futhermore, our results show that the formation of PAR was increased by 
preconditioning doses of NMDA in a TIQ-A-dependent manner (Fig. 36 B)., Finally, we 
observed that the increase in H3 (K18) acetylation induced by NMDA preconditioning, 
was significantly prevented by TIQ-A, whereas the increase in PAR formation was 
similarly prevented by SAHA (Fig. 16 B), thus suggesting a possible interaction 
between PARP and HDAC activities in the development of ischemic tolerance. We can 
exclude a direct action on PARP pure enzyme, because the HDAC inhibitor SAHA is 
not able to block it as compared with the endogenus inhibitor nicotinamide or a potent 
PARP inhibitor PJ34 (Fig. 36 C). 
 
Fig. 36A 
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Fig. 36B Hippocampal slices were exposed to 3 µM NMDA, NMDA + TIQ-A or NMDA + SAHA for 
60 min and then lysed and processed for Western blot with an anti-PAR antibody (Alexis). PARP activity, 
as detected by the formation of PAR, was increased after exposure to a preconditioning concentration of 
NMDA. This increase was prevented when TIQ-A or SAHA were added to the medium. Quantitative 
analysis of Western blots are expressed as percentage of control PARP activity. Bars represent the mean ± 
SEM of at least 4 experiments. **P<0.01 and *P<0.05 vs. control.  
 
 
 
Fig. 36C The activity of purified PARP was measured using a radiolabeled assay. The enzyme uses 
[3H]NAD to form PAR polymers and the extent of PAR formation was assessed by quantification of 
radiation.  Our results show that the HDAC inhibitor SAHA (10 µM) does not directly inhibit purified 
PARP, as compared with 100 µM of the endogenous inhibitor nicotinamide (NAM) or the inhibitor PJ34 
(10 µM). Data are expressed as counts per minute (CPM). Bars represent the mean ± SEM of at least 3 
experiments. **P<0.01 and *P<0.05 vs. control. 
Fig. 36B 
Fig. 36C 
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Working Hypothesis: Fig. 37 
 
 
 
 
 
 
 
 
 
 
 
Fig. 37 
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9. DISCUSSION 
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Ischemic tolerance is an evolutionary conserved cellular defense program in 
which exposure to a subtoxic preconditioning stimulus results in resistance to a 
subsequent lethal ischemic insult (Gidday, 2006; Steiger & Hanggi, 2007; Stenzel-Poore 
et al., 2007; O’Duffy et al., 2007; Obrenovitch, 2008; Dirnagl et al., 2009). The key 
element in this process is the preconditioning stimulus and its ability to regulate 
neuronal activity, involving a number of transductional and traslational pathways that 
generate an array of mechanisms in which specific transducers lead to neuroprotection 
by modifying the gene expression of vulnerable cells.  
A number of possible molecular mediators of ischemic tolerance, that determine 
either inhibition of programmed cell death or augmentation of programmed cell survival 
processes, have been proposed. Among these, the induction pathways triggered by 
activation of ionotropic (iGlu) and metabotropic glutamate (mGlu) receptors have 
received particular attention. Subtoxic concentrations of N-methyl-D-aspartate (NMDA) 
have been used as preconditioning stimuli (Grabb & Choi, 1999; Raval et al., 2003; 
Soriano et al., 2006) and shown to produce neuroprotection through various 
mechanisms, including moderate increases in the concentrations of intracellular calcium, 
the rapid release of brain-derived neurotrophic factor (BDNF), the formation of NO, the 
activation of the Ras/ extracellular signal-regulated kinase (Erk) and 
phosphatidylinositol 3 (PI3)-kinase/Akt pathways, and the increased activity of the 
transcription factor NFκB (Gidday et al., 1999; Shamloo et al., 1999; Gonzalez-Zulueta 
et al., 2000; Bickler and Fahlman, 2004). Similarly, activation of group I mGlu receptors 
of the mGlu1 and mGlu5 subtypes with sublethal concentrations of (S)-3,5-
dihydroxypghenylglycine (DHPG) has recently been demonstrated to represent an 
effective preconditioning stimulus that is able of attenuating the toxic effects of NMDA 
and oxygen-glucose deprivation (OGD) (Blaabjerg et al., 2003; Werner et al., 2007).  
 In our experiments, we observed that DHPG (10 µM), a group I mGlu receptor 
agonist, or NMDA (3 µM) applied to the slices for 30 min 24 h before the lethal OGD or 
AMPA toxic challenge, significantly attenuated CA1 injury. These observations suggest 
that activation of group I mGlu receptors or NMDA receptors are sufficient to trigger 
mechanisms culminating in an increased resistance to ischemic insults (ischemic 
tolerance).  
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The endogenous molecular mechanisms of increased neuronal resistance induced 
by preconditioning represent attractive targets for the development of therapeutic 
strategies, but these processes are still not clearly understood.  
We have examined two different aspects in the induction of ischemic tolerance: 
the modulation of glutamate receptors in the Post Synaptic Density and the changes in 
gene expression.  
For the first point, we have investigated whether MAGUK proteins and glutamate 
receptor responses could be modified in rat organotypic hippocampal slice models of 
pharmacological preconditioning and how AMPA-stimulated inward currents could be 
modified after preconditioning stimulus.  
A previous report of Blaabjerg and colleagues have supported the role of mGluR1 
in neuroprotection against NMDA-induced cell death. In particular, their results show 
that selective activation of group-I-mGluRs with 10 µM DHPG (2h before recording and 
application of NMDA) protect neurons against a subsequent excitotoxic stimulation of 
NMDA receptors in a concentration-dependent manner in hippocampal CA1 and CA3 
subfields in a model of organotypic hippocampal slices (Blaabjerg et al., 2003). These 
data show that DHPG-mediated neuroprotection against NMDA toxicity occurs via the 
mGluR1 receptor (infact, neuroprotection could be reversed by inhibition of the mGluR1 
receptor with LY367385, but not by the mGluR5 receptor antagonist MPEP) and that 
neuroprotective DHPG treatment can greatly reduce NMDA-stimulated currents. A 
similar observation has been made in cerebellar granule cells, in which treatment with 
trans-ACPD or (R,S)-DHPG significantly reduces Ca2+ influx induced by application of 
NMDA or glutamate (Pizzi et al., 1996b) and in mouse cortical cultures where DHPG 
reduced NMDA whole-cell currents (Yu et al., 1997).  
Our results also show that AMPA-stimulated inward currents in voltage-clamped 
CA1 pyramidal cells were significantly decreased, suggesting that activation of group-I-
mGluRs or NMDARs could lead to inhibition of AMPA-receptor function. Our data 
suggest that a possible mechanism may involve modifications of AMPA receptors and 
its downregulation were observed. Infact, 24 h following preconditioning stimulation 
with NMDA preconditioning we observed a reduction in GluR1 AMPA subunit 
expression level in TIF preparation and an increase of the same protein after treatment 
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with a crosslinker BS3, indicating an internalization of AMPA receptor NMDA-
preconditioning induced. No changes were observed in NMDA receptor subunits (NR2a 
and NR2B) or MAGUK proteins (PSD95 and CAMKII) after 24 h of preconditioning 
stimulation in the same experimental conditions. The internalization of AMPA receptors 
could explain NMDA but not DHPG neuroprotection. A possible mechanism by which 
DHPG induces neuroprotection is due probabily to a modulation of presynaptic 
terminals that could reduce the glutamate release (Blaabjerg et al., 2003). Our data 
support this thesis because the value of the AMPA-induced effect on sEPSC frequency 
but not amplitude in DHPG preconditioned slices as compared with control slices was 
significantly reduced 24 h following NMDA/DHPG preconditioning. On the other hand, 
the AMPA-induced amplitude was significantly reduced only after NMDA but not 
DHPG preconditioning indicating a presynaptic involvement for DHPG neuroprotection 
and a postsynaptic involvement for NMDA neuroprotection. 
 
For the second point, we have choose to investigate the contribution of two classes 
of enzymes involved in gene modulation and early studied in our laboratory: PARP and 
HDACs. We know that both NMDA (Eliasson et al., 1997; Lo et al., 1998; Mandir et al., 
2000) and DHPG (Meli et al. 2005) can stimulate the activity of PARP-1, and that the 
dynamic chromatin remodeling events in hippocampal nerurons are associated with 
NMDA receptor-mediated activation and histone modulation (Tian et al., 2009).  
Our study shows that PARP-1 exerts a neuroprotective role in the development of 
ischemic tolerance following our preconditioning paradigms and this activation was 
relatively mild, and was not associated with a significant consumption of cellular NAD+ 
and ATP.  Caspase-3/7 activity also appeared to be necessary for the development of 
ischemic tolerance in these models, but the activation of this enzymatic pathway was 
modest and did not lead to significant cleavage of PARP-1.  
  In an astrocyte-neuron co-culture model, "chemical" ischemic preconditioning 
leads to mild caspase-3 activation and PARP-1 cleavage, suggesting a cause-effect 
relationship between inhibition of PARP-1-mediated cell death pathways and increased 
resistance to a subsequent lethal OGD challenge (Garnier et al., 2003). Caspase-3 
activation and PARP-1 cleavage were also observed in a rat model of ischemic 
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preconditioning in vivo, and were shown to be triggered by sublethal zinc accumulation 
and the consequent activation of p75NTR in neurons (Lee et al., 2008). In a very recent 
report, caspase-3 and PARP-1 appear not to be required for the development of ischemic 
tolerance in a mouse model of focal ischemia (Faraco et al., 2010). Depending on the 
degree and nature of the insult, and especially in conditions that more closely resemble 
the mild or sublethal progressive stress of endogenous preconditioning and perhaps 
chronic neurodegeneration,  PARP-1 activation may play a neuroprotective role.  
    The modest activation of caspase-3 induced by ischemic preconditioning is still 
able to cleave and inactivate PARP-1 (Garnier et al., 2003; Lee et al., 2008), and this 
mechanism has been proposed to confer resistance to neurons against subsequent insults, 
including ischemia, that would otherwise induce PARP-1-mediated cell death. 
Conversly, our DHPG and NMDA preconditioning protocols induced a similar modest 
increase in the activity of caspase-3 and 7, as compared to what observed with 
staurosporine, but were unable to produce significant cleavage of PARP-1. Hence, it 
appears that in our system PARP-1 cleavage occurs only following the substantial 
activation of caspase-3/7 induced by conditions that produce apoptotic cell death, i.e., 
incubation with 10 staurosporine for 24 h (Meli et al., 2004), whereas following DHPG 
and NMDA preconditioning caspase 3/7 is only modestly activated and PARP-1 is not 
cleaved, but rather appears to be necessary for the development of  tolerance to 
subsequent insults in neurons. 
On the other hand, despite the established role of PARP-1 in post-ichemic cell 
death, several reports have demonstrated that PARP-1 activation in physology or in 
conditions of mild cellular stress may be beneficial via multiple mechanisms, including 
DNA excision repair (Nagayama et al., 2000), histone acetylation (Cohen-Armon et al., 
2007) and the activation of the transcription factor NF-κB (Chiarugi & Moskowitz, 
2003), that may support the survival of neurons by inducing the expression of 
antiapoptotic genes (Bhakar et al., 2002). NF-kB is a key transcription factor in the 
regulation of a set of proteins, and PARP has been shown to act as a coactivator in the 
NF-kB-mediated transcription (Oliver et al., 1999). It is nowaday established that 
PARP-1 also regulates the expression of various proteins at the transcriptional level.  
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Poly(ADP-ribosylation) of histones may also contribute to the transcription-
promoting effect of PARP-1, because poly(ADP-ribose) confers negative charge to 
histones, leading to electrostatic repulsion between histones and DNA. Thus, poly(ADP-
ribosylation) can loosen the chromatin structure and can thereby make genes more 
accessible for the transcriptional machinery (Miyamoto et al., 1999).  
The induction of ischemic tolerance is associated with a substantial change in gene 
expression, suggesting that preconditioning stimulates a fundamental genomic 
reprogramming of cells that confers cytoprotection and survival (Stenzel-Poore et al., 
2007). The genomic response after ischemic preconditioning is a signature of the 
complex interplay of multiple signalling pathways. To this aim we investigated the role 
of HDAC in our preconditioning paradigms and a possible interplay between PARP and 
HDAC products. We know that histone acetylation enhances gene transcription  while 
histone deacetylation decrease gene transcription and that protein acetylation is dynamic 
and maintained by two classes of functionally antagonistic enzymes: histone acetylases 
(HATs) and HDACs, which add or remove acetyl groups from protein substrates, 
respectively (Sun et al.; 2003). 
A recent paper by Ting have demonstrated a crucial role for HDAC inhibition in 
protecting the heart against I/R injury in both early and delayed pharmacologic 
preconditioning and an essential role of p38 in mediating protection elicited by HDAC 
inhibition. HDAC inhibition causes a dramatic increase in p38 activity in 
pharmacologically preconditioned hearts, further supporting that HDAC inhibition with 
p38 activation is critical to achieve cardioprotection (Ting et al.; 2007).  
Our results show that HDAC inhibitors are not able to induce tolerance by itself in 
a model of organotypic slices while are able to revert the neuroprotection induced by 
NMDA preconditioning stimulus. A possible mechanism of NMDA neuroprotection 
could be do to an increase in histones acetylation that confer in a gene molulation and 
finally in cell resistance and neuroprotection. According to this point, 3h after the 
NMDA preconditioning stimulus we observed  a sligh increase in H3 (K18) acetylation 
as compared with the dramatic increase induced by the HDAC inhibitor SAHA (Fig. 
36A). Faraco and colleagues have demonstrated that in the ischemic brain tissue 
subjected to 6 h of middle cerebral artery occlusion, histone H3 acetylation levels 
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drastically decreased, without evidence for a concomitant change of histone acetyl-
transferase or deacetylase activities. Treatment with SAHA (50 mg/kg i.p.) increased 
histone H3 acetylation within the normal brain (of approximately 8-fold after 6 h) and 
prevented histone deacetylation in the ischemic brain (Faraco et al.; 2006). The 
acetylation level of histones seems to be very important for the destiny of cell survival. 
During neurodegeneration, critical loss of HAT protein level ensue a rebated HAT dose 
and activity. This unbalances the acetylation towards excessive deacetylation of target 
moieties (see the figure 38). We can add that in preconditionant conditions, an excessive 
level of histone acetylation induce to cell death probabily by upregulating gene 
expression and limiting the normal preconditionant mechanisms that induce to neuronal 
resistance. 
 
 
 
 
 
Fig. 38 Saha RN, Pahan K. (2006) Cell Death Differ. 13(4):539-50. 
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Futhermore, we observed that the increase in H3 (K18) acetylation was 
significantly prevented by the PARP inhibitor TIQ-A, whereas the increase in PAR 
formation induced by the same NMDA preconditioning stimulus was similarly 
prevented by HDAC inhibitor SAHA (Fig. 36 B). This suggest a possible interaction 
between PARP and HDAC activities in the development of ischemic tolerance. We can 
exclude a direct action on PARP pure enzyme, because we have observed that SAHA is 
not able to block PARP activity as compared with the endogenus inhibitor nicotinamide 
or a potent PARP inhibitor PJ34 in an in vitro dosage (Fig. 36 C).  
A recent paper pubblished by Krishnakumar suggests a possible interplay between 
PARP-1 and histone 1 at promoter specifies transcriptional outcomes caused by a similar 
nucleosome-binding properties and effects on chromatine structure in vitro 
(Krishnakumar et al., 2008). A review of Schreiber talks about poly(ADP-ribosylation) 
of histones H1 and H2B and relaxation of DNA structure and repair mediated by this 
covalent interaction (Schreiber et al.; 2006). Cohen-Armon and colleagues had 
demonstrated that poly (ADP-ribosylation) mediate erk-induced acetylation of core 
histones. In particular, phosphorylated ERK shuttles between the cytoplasm and nucleus 
and interact with PARP-1, enhancing PARP-1 activation and auto-polyADP-
ribosylation. PolyADP-ribosylated PARP-1 acts as an anchoring protein for 
phosphorylated ERK2 in the nucleus and acts as a scaffold protein, enhancing ERK-
catalyzed phosphorylation of transcription factor Elk1(see the figure 39).  
 
Fig. 39 
Cohen-Armon M. (2007) Trends Pharmacol Sci. 28(11):556-60 
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We hypothesized that Erk phosphorylated could be a link that can explain the interplay 
between poly(ADP-ribosyl)ation and H3 acetylation induced by NMDA preconditioning 
protocol in our organotypic hippocampal slices. Our results showed that the formation of 
PAR was increased by preconditioning doses of NMDA in a TIQ-A or SAHA -
dependent manner. We observed that the increase in H3 (K18) acetylation induced by 
NMDA preconditioning, was significantly prevented by TIQ-A. Erk could be 
responsible for the interplay between poly(ADP-ribosyl)ation and histone acetylation in 
our model of preconditioning. Futhermore, our results show that NMDA preconditioning 
induce an increase in Erk½ phosphorylation suggesting a new via diverse signal 
transduction mechanisms (date not shown).  
  In conclusion, our results suggest that under conditions of sublethal cellular 
stress, such as those evoked by DHPG and NMDA preconditioning in our in vitro 
models of ischemic tolerance, mild activation of caspase 3/7, PARP-1 and HAT may 
produce a neuroprotective response. Because PARP inhibitors and HDAC inhibitors 
have entered the stage of clinical testing for the treatment of cancer (Horvath and Szabo, 
2007; Liang and Tan, 2010) and are currently under investigation as potential 
therapeutic agents in stroke and neurotrauma (Komjati et al., 2005; Moroni and 
Chiarugi, 2009), our results indicate that caution should be exercised when considering 
the use of PARP-1or HDACs inhibitors in the presence of chronic neurodegenerative 
diseases. 
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10. CONCLUSIONS 
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In conclusion, our results show that: 
 
1. Organotypic hippocampal slices exposed to sublethal doses of DHPG or NMDA 
develop tolerance to a toxic challenge of 30 min OGD applied 24 h later. 
 
2. Organotypic hippocampal slices exposed to 3 µM NMDA for 60 min or to 10 
µM DHPG for 30 min develop tolerance to a subsequent toxic challenge of 10 
µM AMPA for 24 h. 
 
3.  The reduced AMPA response and toxicity following DHPG preconditioning are 
NOT mediated by GluR1 internalization but only by a pre-synaptic mechanism.  
 
4. The reduced AMPA response and toxicity following NMDA preconditioning 
appears to be mediated by a post-synaptic GluR1 internalization and by a 
simultaneous pre-synaptic mechanism.  
 
5. PARP and HDACs are involved in the development of ischemic tolerance 
following DHPG and NMDA preconditioning, possibly by playing a 
neuroprotective role. 
 
6. The activation of PARP following DHPG or NMDA preconditioning leads to 
mild consumption of cellular NAD+ and ATP.  Under our experimental 
conditions, caspase-3 is activated but leads only to a minimal cleavage of PARP. 
 
7. The increase of acetylation in K18 of H3 following NMDA preconditioning is 
prevented by the PARP inhibitor TIQ-A. The activation of PARP following 
NMDA preconditioning is prevented by the HDAC inhibitor SAHA. 
 
8. We hypothesize an interaction between PARP and histone acetylation in the 
development of ischemic tolerance. 
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